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 INTRODUCTION 
 
 
 “The aerobic life style offers great advantages, but is fraught with danger” (51)
 
 
1.1 Oxygen Radicals and Antioxidative Defense System 
 
Utilizing oxygen enables living cells to use much more energy than anaerobic 
organisms, but this is a two-edged sword. In one way it offers great advantages regarding 
energy metabolism and host defense, but products of its metabolism (reactive oxygen species, 
ROS) may also lead to damage of cells and tissues. ROS are mainly generated as a side product 
of the respiratory chain and can cause modifications of proteins, lipids, and DNA especially 
when present in high concentrations. ROS are not only detrimentary to cells, they are also 
involved in cell signaling and host defense. To maintain the balance of cellular ROS, a 
complex defense system (Antioxidative defense system or AOS) against high levels of ROS has 
been developed allowing aerobic organisms to live in such an environment.  
Owing to its own electronic configuration, oxygen is prone to gain electrons and is thus 
a potent oxidant. During the respiratory process, O2 is progressively reduced by a controlled 
supply of four electrons to yield water: 
 
O2 + 4e- + 4H+ → 2 H2O 
 
Incomplete reduction of O2, with a gain of one, two or three electrons is, however, 
possible and leads to the formation of chemical entities (ROS) that are still potent oxidants. 
The usually well controlled enzymatic systems that use electron transfer reactions may exhibit 
some leakage, and in the presence of oxygen any such electron leakage may result in ROS 
production. ROS are generated either exogenously or produced intracellularly from several 
different sources. Exogenous sources generating ROS are ultraviolet light, ionizing radiation, 
chemotherapeutic agents, inflammatory stimuli and environmental toxins (50). The majority of 
intracellular ROS are generated during respiration in mitochondria. Electron transport through 
the mitochondrial respiratory chain is extraordinarily efficient, only 1-2% of electrons leak out 
and are partly reduced to superoxide anion. The production of mitochondrial superoxide 
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radicals occurs primarly at two discrete points in the electron transport chain, namely at 
complex I (NADH dehydrogenase) and at complex III (ubiquinon-cytochrom c reductase). 
Under normal metabolic conditions, complex III is the main site of ROS production (135). The 
leaking point of this system is the formation of free radical semiquinone anion species (.Q-) 
that occurs as an intermediate in the regeneration of coenzyme Q. Once formed, .Q- can readily 
and non-enzymatically transfer electrons to molecular oxygen with the subsequent generation 
of superoxide radicals. This activated oxygen molecule can react with organic substances by 
noncatalytic means. ROS are also formed in the endoplasmatic reticulum, liposomes, cell 
membranes, macrophages, peroxisomes and in the cytosol (33). Enzyme systems contributing 
to oxidative stress include NADPH cytochrome P450 reductase in the endoplasmatic 
reticulum, hypoxanthine/xanthine oxidase, glucose oxidase, monoamine oxidase, 
lipoxygenases, cyclooxygenase and NADPH oxidase (50, 80, 96). 
The most common forms of ROS include superoxide anion (O2&-), hydrogen peroxide 
(H2O2), the highly reactive hydroxyl radical (&OH), singlet oxygen (1O2), peroxyl radical 
(RO2&), alkoxyl radical (RO&) and hydroperoxyl radical (HO2&) (96). The production of the 
various radicals is linked via chemical or enzymatic reactions and ROS can give rise to 
secondary reactive products such as lipid peroxides. The most common intracellular forms of 
ROS are listed in Table 1, together with their main cellular sources of production and the 
relevant enzymatic antioxidant systems scavenging these ROS molecules. 
 
Table 1: The major ROS molecules and their metabolism 
ROS molecule Main source   Enzymatic defense systems Product(s) 
Superoxide (O2&-)  Leakage of electrons  superoxide dismutase (SOD)  H2O2 + O2
  from the electron transport chain  superoxide reductase  H2O2
Activated phagocytes,  
Xanthin oxidase, flavoenzymes 
Hydrogen peroxide (H2O2) From O2&- via SOD  Glutathione peroxidase  H2O2 + GSSG 
NADPH-oxidase  Catalase    H2O + O2
Xanthine oxidase   Peroxiredoxin (Prx)  H2O 
Glucose oxidase 
Hydroxyl radical (&OH) From O2&- and H2O2 via    
transitions of metals (Fe and Cu) 
Nitric oxide (NO) Nitric oxide synthase  Glutathione/TrxR   GSNO 
 
Adopted from Nordberg and Arner, Free Radical Biology & Medicine, 2001 (100) 
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Free radicals and nonradical reactive molecules derived from radicals exist in cells and 
tissues at low but measurable concentrations. Their concentration is determined by the balance 
between their rates of production and their rates of clearance by various antioxidant 
compounds and enzymes (41). When they are present in low (physiological) concentration, 
ROS have been implicated in the regulation of diverse cellular functions including defense 
against pathogens, intracellular signaling, transcriptional activation, proliferation, and 
apoptosis (34). Upon bacterial activation, phagocytes produce ROS (HOCl and &OH) in 
amounts sufficient to kill invading bacteria (129) and this is an essential host defense 
mechanism necessary to combat infection.  
ROS stimulate cell proliferation in smooth muscle cells, fibroblasts, amnion cells, 
prostate cancer cells and aortic endothelial cells (119), and are thought to act as subcellular 
messengers for certain growth factors (IL-1β, IL-6, IL-3, TNF-α). ROS also function as 
physiological mediators of transcriptional control. Redox-sensitive transcription factors are 
Nuclear Factor-κB (NF-κB) and Activation Protein-1 (AP-1) (100), Sp-1, c-Myb, p-53, egr-1 
and hypoxia-inducible factor (Hif-1) (119). Several proto-oncogenes are known to be 
transcriptionally activated by increased cellular oxidation such as jun-B, jun-D, c-fos, and fos-B 
(2). In the regulation of apoptosis ROS have a dual function. They induce apoptotic pathways 
through the production of ceramide (137), the activation of JNK (73, 137), p53 (133, 153), 
ASK-1 (21), p38 (21) and the induction of the regulatory domain of PI 3-kinase, p85 (153), or 
the combined activation of several pathways, but may also prevent apoptosis through the 
activation of NF-κB including NF-κB target genes (103), MAP kinase (55), Akt (81) and Hsp 
27 (62), or by NO-mediated supression of caspases through a cGMP-dependent mechanism 
and direct inhibition of caspases by protein S-nitrosylation (NO activity) by NO (80). Thus, 
ROS perform their dual role in cell survival and cell death through a cross talk between the 
apoptotic machinery and cellular signaling mechanisms.  
All these observations suggest that free radicals have an influence on molecular and 
biochemical processes and may directly affect cellular processes (2).  
Imbalance of cytoplasmic ROS may result in potentially cytotoxic “oxidative stress”. 
Under these pro-oxidant conditions, highly reactive radicals are formed prone to cause damage, 
and thereby to be potentially toxic, mutagenic, or carcinogenic. The targets for ROS damage 
include all major groups of biomolecules: DNA, RNA, proteins, and lipid components. ROS 
such as &OH and peroxynitrite (ONOO-) cause alterations of DNA, e.g. cleavage of DNA, 
oxidation of and nitration of DNA bases, and generation of DNA-protein cross links. Chemical 
modification of bases may result in mutations due to erroneous base paring during replication. 
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ROS may also damage  lipids through the reaction with polyunsaturated fatty acids, a process 
known as lipid peroxidation. The radical chain reaction starts with segregation of a hydrogen 
atom from polyunsaturated fatty acids, is followed by formation of highly toxic lipid (L·) and 
peroxyl radicals (LOO·), and ends with damage of biological membranes.  
To protect themselves against increased levels of ROS, referred to as oxidative radical 
stress, cells possess several antioxidant systems that tightly regulate and determine a balance 
between the rate of ROS production and clearance. Antioxidants are defined (58) as substances 
that are able to compete at relatively low concentration with other oxidisable substrates. They 
are thus able to significantly delay or inhibit the oxidation of these substrates. 
Antioxidant defense systems (AOS) can be divided in two major groups, enzymatic and 
nonenzymatic systems. Antioxidant enzyme systems include the enzymes superoxide 
dismutase (SOD), superoxide reductase (SOR), catalase (Cat), thioredoxins (Trx) and 
thioredoxin reductases (TrxRs), peroxiredoxines (Prx), glutathione peroxidase (GPx), 
glutathione reductase (GR) and other GSH-related enzyme systems. Nonenzymatic compounds 
active in AOS are α-tocopherol (vitamine E), retinol (vitamine A), β- carotene, coenzyme Q, 
lipoic acid, ascorbate (vitamine C) and thiol reducing systems consisting of small molecules 
with redox active sulfhydryl moieties such as glutathione (GSH). In addition there are 
compounds that have a relatively low specific antioxidative activity on a molar basis, but can 
contribute significantly to the overall antioxidant defense system when present at high 
concentration. The most prominent examples of such high-level, low-efficiency antioxidants 
are free amino acids, metabolic intermediates and small molecules (e.g. cysteine, histidine, 
pyruvate, bilirubin, α-thioglycerol, β-mercaptoethanol), peptides and proteins (e.g. albumin, 
transferrin, metallothioneins, ceruplasmine etc.) (41).  
 
This work is going to deal with an antioxidant defense system that regulates the uptake 
and intra- and extracellular concentration of cysteine.  
 
 
1.2 Burkitt Lymphoma Cells and Oxidative Stress 
 
Burkitt lymhoma (BL) is a malignant human B-cell tumor occurring at high incidence 
in children in tropical areas of Central Africa and New Guinea (29) and with a lower incidence 
all over the world (86). Virtually all the cases arising in high incidence areas are associated 
with Epstein-Barr virus (i.e. they carry the genetic viral information), whereas only 10 to 20 % 
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of the cases in low incidence areas are associated with EBV. EBV positive BL cells in vivo 
only show expression of EBNA1, a viral antigen required for maintaining multiple episomal 
copies of the viral genome in the tumor cells (107). Induction of EBV latent genes causes a 
shift in the phenotype of the cells from that of BL cells (group I- phenotype) in vivo to a 
phenotype similar to that of EBV-immortalized lymhoblastoid cell lines (LCL) (group-III 
phenotype). A hallmark of Burkitt lymphomas are translocations of the proto-oncogene c-myc 
into one of the immunoglobulin loci resulting in constitutive activity of this transcription 
factor. Moreover, mutations of the gene encoding the tumor suppressor p53 are found in one 
third of the cases of Burkitt lymphoma (24, 52), and there is also evidence for genetic 
alterations of the putative tumor suppressor gene retinoblastoma-like 2 (RB2) in most cases of 
endemic Burkitt lymphoma and some sporadic cases (31). 
During the attempt to establish cell lines from BL cases from low-incidence areas, 
Lenoir et al. (1985) noted that the use of feeder layer of irradiated human fibroblasts greatly 
improved the frequence of outgrowth of cell lines (87). Most of these cell lines became feeder-
independent upon prolonged in vitro cultivation. However, some cell lines (EBV-positive 
group I and EBV-negative BL cells) retained a significant feeder dependence when cultured at 
suboptimal conditions (low cell density or low FCS concentration) (44). Modulating the 
susceptibility of BL cells to apoptosis by changing the culture conditions has become an 
important model system to study the role of EBV and viral gene products in the regulation of 
apoptosis (45).  
Burkitt Lymphoma (BL) cells are highly sensitive to suboptimal growth conditions in 
vitro and undergo apoptosis when seeded at reduced serum concentration or low cell density. 
However they are protected from apoptosis and proliferate on a feeder layer of irradiated 
fibroblasts (45). Irradiated fibroblasts can protect BL cells from apoptosis through secretion of 
a survival- and proliferation-promoting activity that is soluble and labile. 
At the beginning of the seventies it had been shown that a mouse lymphoma cell line 
was dependent for its growth on  the presence of “an activated serum component”. This growth 
factor was found to be inactive in foetal calf serum (FCS) but could be activated by β-
mercaptoethanol (2-ME) and by macrophages (61). A similar observation was made by 
Broome and Jeng (1973) (27) who found that 13 out of 22 leukemic and neoplastic lymphoid 
cell lines were dependent on the presence of a thiol-containing compound for their growth in 
vitro.  
Detailed biochemical studies by Bannai and his coworkers have elucidated the 
molecular mechanism how 2-ME acts as a growth factor for murine B cell lymphoma lines 
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(11-13, 65, 67-69, 71). Murine lymphoma cells have a limited uptake capacity for cystine. As 
cystine is the only avalaible source of cystine/cysteine in the medium, the limited uptake 
capacity of cystine thus limits their growth. 2-ME forms a mixed disulfide with cystine. This 
mixed disulfide is taken up into the cell via an amino acid transport system for bulky amino 
acids that is shared with methionine. Intracellularly, the mixed disulfide is reduced releasing 
cysteine and 2-ME. As the supply of cysteine is the rate limiting step for the synthesis of 
glutathione, cysteine is rapidly incorporated into glutathione. 2-ME is secreted and can react 
extracellularly with another cystine molecule to initiate another round of cysteine import. Even 
if the growth medium is completely oxidized and lacks any free sulfhydryl groups, 2-ME is 
able to sustain a highly efficient amino acid uptake shuttle system for cysteine in murine B 
cells.  
For a long time the effect of 2-ME has been believed to be restricted to mouse 
lymphoma cells and not to operate in human cells. Paradoxically, addition of 2-ME to human 
BL cells induced cell killing rather than survival and cell proliferation (45). It could be shown 
in our laboratory, however, that α-thioglycerol (α-TG) as well as 2-ME and dithiothreithol 
(DTT) can indeed efficiently promote the uptake of cysteine into BL cells provided that 
formation of ROS through reduction of molecular oxygen by the thiol-containing compound 
was prevented by the addition oxygen scavengers, like sodium pyruvate, catalase or 
bathocuproine disulfonate (BCS) (26). Sulfhydryl containing compounds can efficiently reduce 
molecular oxygen by the Fenton reaction if trace amounts of transition metals are present in the 
medium or serum. Addition of oxygen radical scavengers and/or chelators of transition metals 
was thus necessary to dissect the cell death inducing effect of thiol compounds from their 
survival and growth promoting effect. Similarly to mouse B lymphoma cells, also in human BL 
cell the availability of cysteine turned out to be the rate limiting factor for the synthesis of 
glutathione and thus for the ability of the cells to cope with oxidative stress (72). Similarly to 
mouse B cells, BL cells have a low capacity for uptake of cystine which is the only available 
source of cysteine in the medium and is taken up through the cystine-glutamate exchange 
transporter also called system xc-. On the other hand irradiated fibroblasts take up cystine 
readily from the medium through system xc-, reduce it intracellulary to cysteine and secrete the 
surplus of cysteine into the medium thus providing to cocultured BL cells sufficient amounts of 
cysteine that is taken up by the ASC system, a shared amino acid transporter for alanine, serine 
and cysteine (Fig. 1). 
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B cell
cys-S-S-cys
pyruvate cys-SH glutamine
Irradiated fibroblast cys-SH cys-S-S-cys
glutamate
NH3
XC-
glutathione
 
 
Figure 1. Metabolic interaction between fibroblasts and B Cells 
 
1.3 The Heterodimeric Amino Acid Transporters 
 
The heterodimeric amino acid transporters belong to a group of cell surface antigens of 
leukocytes that are involved in diverse processes such cell adhesion and activation through 
integrins, migration, differentiation, regulation of cell fusion by viral proteins as well as 
regulation of proliferation and apoptosis (38). 
The cystine glutamate exchange transporter belongs to the glycoprotein- associated 
amino acid transporter family (gpaAT). Generally, amino acid transporters together with 
peptide transporters accomplish the uptake of amino acids and are involved in basic cellular 
functions like regulation of cell volume, synthesis of glutathione (GSH), provision of amino 
acids for protein synthesis, and energy metabolism (144). According to their specialized 
functions amino acid transporters are divided into different families that are distinguished by 
the functional properties (specificity of amino acids transported, transport mechanism, coupling 
to ions) and their molecular similarity or dissimilarity. Recently, a new large family of 
heterodimeric amino acid transporters has been discovered that is unique in its functional and 
molecular properties.  
These transporters are heterodimers of aproximately 120 kDa composed of two subunits 
linked by a disulfide bond (Fig. 2). 
 
 9
INTRODUCTION 
 
 
 
Figure 2. Structure of glycoprotein-associated amino acid transporters 
 
One subunit is referred to as heavy chain. The heavy chain is a highly glycosylated 
polypeptide of 80 kDa (529 aa). The other subunit is referred to as the light chain, a protein of 
40 kDa with 12 putative transmembrane domains. The substrate specificity depends on the 
nature of the light chain. The name “glycoprotein-associated” amino acid transporters is based 
on a common feature of the members of this family that their functional cell-surface expression 
depends on the association of the light chain with a heavy chain. The heavy chain is a type II 
surface glycoprotein, either 4F2hc (CD98) or rbAT (D2) (139). 
 
1.3.1 The Heavy Chains rbAT and 4F2hc 
 
Two different types of heavy chains were described. The first identifed heavy chain of 
the heterodimeric amino acid transporter family was rbAT, independently isolated by three 
groups by expression cloning (22, 127, 147). This heavy chain is a component of b°,+ 
transporters of neutral and dibasic amino acids. The second identified heavy chain subunit is 
the 4F2 heavy chain (4F2hc) (22, 148), previously identified and cloned as a surface antigen 
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expressed on activated lymphocytes and later renamed as CD98 (59, 90, 105, 128). The two 
heavy chains rbAT and 4F2hc exhibit about 30% identity and 50% similarity and are 
associated with different light chains thus forming different amino acid transporters (22). 
Analysis of the amino acid sequences suggests that both heavy chains contain a single 
transmembrane domain (helix) (83-106 amino acids), with the NH2 terminus intracellulary 
localized (22, 23). The COOH terminus is presented as a globular glycosylated extracellular 
domain. Both proteins have therefore been classified as type II membrane proteins. In both 
heavy chains, cysteine 109 forms the disulfide bond with the light chain. 
 
1.3.2 The Light Chains 
 
The light chains of the heterodimeric amino acid transporters belong to a family of 
homologous proteins with similar molecular weight and membrane topology. The light chains 
are markedly hydrophobic proteins of 502-535 anmino acids and contain 12 putative 
transmembrane domains (see figure 2) with NH2 and COOH termini located intracellularly 
(38). So far, seven cDNAs encoding distinct light chains have been identified. These are LAT1, 
LAT2, y+LAT1, y+LAT2, ascAT1, b0+AT1 and xCT. All light chains identified to date function 
as amino acid transporters when associated with a heavy chain and the substrate specifity of the 
heterodimer depends on the nature of the light chain. A heavy chain is needed for trafficking a 
light chain to the plasma membrane. 
Interaction between heavy and light chains occurs via a disulfide bridge between Cys 
109 of the heavy chain and a conserved cysteine residue between transmembrane helixes TM3 
and TM4 in the different light subunits (91, 97, 104, 146). The functional role of the disulfide 
bridge has, however, remained elusive. It is neither required for trafficking of the transporter to 
the membrane nor for the amino acid transport function (37, 97, 104, 143). The conservation of 
the cysteine residues involved in the formation of the disulfide bond in all heavy and light 
chains, suggests, nevertheless a functional role. Given the functional heterogeneity of proteins 
sharing 4F2hc, disulfide bond formation may be important to ensure that less abundant 
heterodimers with distinct function can be formed at sufficient rate and that these heterodimers 
exhibit sufficient stability to fulfill their function (37, 48). There are still several open 
questions regarding the functional role of glycoprotein associated amino acid transporters in 
cell proliferation, integrin function and cell adhesion, cell fusion and possibly other important 
processes (139, 142). 
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1.4 The Cystine Glutamate Antiporter 
 
The Cystine Glutamate Antiporter (xc- system) is one of the seven members of the 
glycoprotein associated amino acid transporter family. It consists of two polypeptide chains, 
xCT light chain and 4F2heavy chain (4F2hc). The light chain (xCT) determines the substrate 
specificity. The heavy subunit 4F2hc is responsible for the trafficking of the heterodimer to the 
plasma membrane. The membrane topology of the cystine glutamate antiporter is probably 
very similar to that of other amino acid transporters that share the 4F2 heavy chain subunit 
(Figure 3), although the substrate specificity is markedly different. 
The system has been first described as system xc- by Bannai and Kitamura in 1980 (16) 
and has finally been molecularly identified by expression cloning from mouse activated 
macrophages by Sato and Bannai in 1999 (116). The cystine glutamate antiporter is a plasma 
membrane-localised, Na+ independent, anionic amino acid exchange transport system highly 
specific for glutamate and cystine. Under physiological conditions the antiporter mediates the 
influx of cystine and the efflux of glutamate, because the cystine concentration is very low in 
the cytosol due to its rapid reduction to cysteine, and conversely, the concentration of 
glutamate is much higher inside the cell than in the extracellular fluid due to the activity of 
different isoforms of the amino acid transport system XAG  and the uptake of glutamine which 
is converted intracellularly to glutamate by deamination (14, 20). The gradient of substrate 
concentration across the plasma membrane determines the direction of the exchange reaction 
through system xc-. Cystine is transported only in its mono-anionic form in a molar ratio of 1:1 
with glutamate. The cystine/glutamate exchange by system xc- is thus electroneutral (114).  
As mentioned, the xCT light chain determines the substrate specificity of system xc-. 
The cDNA for mouse xCT encodes a putative protein of 502 amino acids and a relative 
molecular mass of 55.5 kDa. Three different xCT transcripts (12, 3.5 and 2.5 kb) have been 
identifed after treatment of macrophages for 8 hours with LPS and/or diethylmaleate (116). 
The different transcripts are formed by alternative splicing, use of alternative polyadenylation 
sites or a combination of both. 
The conserved cysteine residue at position 158 of xCT is the putative site of disulfide 
bond formation with Cys109 of 4F2hc (116). Cysteine at position 327 (Cys327) in the middle of 
the eighth transmembrane domain of the xCT light subunit has recently been shown to be a 
functionally important residue accessible to the aqueous extracellular environment that is 
presumably structurally linked to the permeation pathway and/or the substrate binding site 
(75).  
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Two clones for human xCT were isolated from a cDNA library derived from human 
fibroblasts. The first clone consists of 1,861 bp and contains a single open reading frame that 
encodes a putative protein of 501 amino acids. Another clone is composed of 5,626 bp and 
contains the same single open reading frame. This second clone has a long 3’-untranslated 
region. The human and murine xCT mRNAs of different size have 3’-untranslated regions of 
different lengths suggesting that the untranslated region might be involved in regulating the 
expression of xCT at a post-transcriptional level (117). The human xCT gene is localized at 
chromosome 4q28-31. The xCT gene is composed of twelve exons. The activity of the cystine 
glutamate exchange transporter contributes to the maintenance of intracellular glutathione 
levels (19). The activity of system xc- is significantly induced by various stimuli, including 
diethylmaleate (DEM), arsenite, cadmium chloride, hydrogen peroxide, bacterial 
lypopolisacharide, and TNF-α in mouse peritoneal macrophages (18, 113). A consequence of 
induction of xc- activity is an increase in the level of intracellular glutathione suggesting that 
system xc- belongs to the category of stress proteins that are required for the metabolic response 
to oxidative stress. It has been shown recently that EpRE-like sequences (electrophile response 
elements like sequences) in the 5’ flanking region of xCT gene are responsible for DEM 
induction of xCT (112). Sequence analysis identified four (EpRE)-like sequences (designated 
EpRE-1 to EpRE4), between –230 and –1 in the 5’ flanking region in front of the first exon.  
 
1.4.1 Physiological Role of the Cystine Glutamate Antiporter in the Cellular 
Antioxidative Defense System 
 
The availability of cysteine is the rate-limiting step for the synthesis of glutathione 
(GSH), the major cellular antioxidant (19). Transport of cystine across the cell membrane is 
essential for the synthesis of glutathione. Outside of cells, cysteine is unstable and readily 
oxidized to cystine with a half life of 0.5-1 hour in the culture medium (66). Therefore cystine 
is predominant in plasma as well as in cell culture medium, and is the only available source of 
cysteine for the cells. The cystine glutamate antiporter imports cystine into the cells in 
exchange with glutamate in a molar ratio of 1:1. Intracellularly, cystine is immediately reduced 
to cysteine, which in turn is used for the synthesis of glutathione and protein synthesis (Fig. 3). 
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Figure 3. Physiological role of cystine glutamate antiporter 
 
Part of cysteine is released back into medium via the neutral ASC amino acid transport 
system and reoxidized to cystine by oxygen (17). Sato et al. have thus proposed that system xc- 
drives a cycle, called the cystine/cysteine cycle, that maintains the balance between cystine and 
cysteine in the culture medium (114). Thereby system xc- contributes to the maintaince of the 
redox state in the cerebral spinal fluid (CSF). Cysteine and cystine, and glutathione and 
glutathione disulfide, are the critical components that are acting as cellular redox buffers in 
metabolism and homeostasis (36). Electrophilic agents as well as chemical and physical stress 
induce the activity of the cystine glutamate antiporter in a variety of cells such as macrophages, 
neuronal or glial cell, fibroblasts, kidney cells, pancreas cells, and hepatocytes (9, 10, 17, 70, 
94, 115). The activity of system xc- directly regulates the intracellular GSH concentration (114) 
and thus can be categorized as part of the cellular antioxidant defense system.  
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1.5  Glutathione (GSH) 
 
Glutathione (GSH) is a tripeptide (L-γ-glutamyl-L-cysteinyl-glycine) and the 
predominant non-protein sulfhydryl compound in the cell. Inside the cell, glutathione is present 
in millimolar concentration (1-10 mM) predominantly in reduced form (GSH) and to a lesser 
extent (about 1% of GSH) in disulfide form (GSSG) ((3, 82). GSSG is formed by disulfide 
bond formation of two GSH molecules (Fig. 4).  
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Figure 4. Structure of the reduced (GSH) and dissulfide (GSSG) form of glutathione 
 
 
1.5.1  Role of Intracellular Glutathione 
 
Glutathione has several functions intracellulary. One of the most important functions of 
glutathione is the protection against oxidative damage caused by reactive oxygen species 
(ROS). As shown in figure 5, glutathione is the major scavenger of hydroxyl radicals, 
peroxides and lipid peroxides inside the cell. Glutathione reacts with ROS and during this 
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process the reduced form of glutathione (GSH) is converted to the disulfide form. Glutathione 
disulfide (GSSG) is again reduced to GSH by NADPH through a reaction catalyzed by 
glutathione reductase (GR). NADPH is formed through the activity of glucose 6-phosphate and 
6-phosphogluconate dehydrogenase in the pentose phosphate cycle. 
 
OH H O+GS2
GSH R
RH
RH+GS +GS GSSG
NADPH
NADP+
ROO ROOH+GS
2 GSH
GR
O2
. . .
.
..
 
 
Figure 5. Reactions of glutathione with ROS 
 
Glutathione does not react directly with hydroperoxides, but is used as a substrate for 
glutathione peroxidases (GSHPx) which catalyze the destruction of H2O2 and lipid peroxides at 
the expense of reduced glutathione (3, 40):  
 
H2O2 + 2GSH → 2H2O + GSSG 
ROOH + 2GSH → 2ROH + GSSG 
 
The disulfide form of glutathione (GSSG) is normally present in the cell at a level of 
about 1% of total glutathione. During oxidative stress the concentration of GSSG increases, but 
this is transient as reduction of GSSG by glutathione reductase is a rapid process. GSSG can 
also exchange sulfhydryl groups with proteins leading to protein-glutathione mixed disulfides 
(40): 
GSSG + protein-SH ⇔ protein-SSG + GSH 
 
Mixed disulfides of proteins with glutathione (protein-SSG) have a longer half-life than 
GSSG, and a significant basal level of glutathionylated proteins is found in cells (88). By 
keeping proteins in different states, this exchange reaction may provide a mechanism for the 
action of GSH in cell signaling. 
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Glutathione has several other functions in cells (3, 35, 93, 121): in amino acid transport 
through the action of the γ-glutamyl cycle, in synthesis of nucleotides as a donor of hydrogen 
(125), in the biosynthesis of leukotrienes, in the detoxification of xenobiotics, and as a 
reservoir for cysteine. Glutathione´s role in detoxification processes is linked to the activity of 
the glutathione-S-transferases. This group of enzymes catalyzes the conjugation of the reduced 
form of glutathione (GSH) to a variety of electrophilic compounds thus rendering them water-
soluble. Conjugation with GSH is an essential step in the detoxification of hepatic toxins 
including xenobiotics, epoxides and carcinogens. The reaction is performed as follows:  
 
R-X + GSH → R-SG + HX  
R-SG + GSH → RH + GSSG 
 
X is an electrophilic compound of exogenous origin. 
 
1.5.2  Compartmentation of Glutathione 
 
The majority of glutathione in cells is synthesized and present in the cytoplasm in two 
forms, as a free glutathione and bound glutathione. Glutathione is also utilized for a variety of 
physiological functions in other cellular compartments, including the nucleus, mitochondrial 
matrix, endoplasmic reticulum, microsomes and extracellular space (124).  
The intracellular compartmentation of glutathione is important for cells that are exposed 
to toxic compounds or to oxidative stress, because the various cellular organelles appear to 
have their own GSH pool independent from the cytosol. 
The nuclear glutathione pool represents 5 to 10% of the total cellular glutathione. In the 
nucleus, glutathione maintains the redox state of critical protein sulfhydryl groups, which are 
necessary for DNA repair and gene expression (5). Glutathione in the nucleus is critical to the 
cell’s well-being and is therefore maintained as a distinctly regulated pool that is protected 
from depletion when levels of GSH in the cytosol fluctuate. Although, the majority of the 
glutathione concentration in the nucleus is equivalent to that in the cytosol and most of the 
GSH present in the nucleus is likely to be in free equilibrium between the cytosolic and nuclear 
compartments, probably exchanged via nuclear pores (124), some studies (42, 74) have 
suggested that at least a portion of the nuclear glutathione pool is “protected” from depletion 
and can maintain its levels. This subnuclear pool of GSH is not in equilibirum with the 
cytosolic GSH pool and presents about 1-2% of the total cellular GSH pool and is believed to 
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play an important role in protecting biochemical processes when the cell is faced with 
fluctuations in cytosolic GSH concentration.  
The mitochondrial pool of glutathione is approximately 30% of total cellular 
glutathione (~ 5mM) (124) and it plays the major role in the maintenance of the mitochondrial 
thiol-disulfide status. Different mitochondrial proteins like dehydrogenases, ATPases, and 
transport proteins, contain essential sulfhydryl groups that must be reduced to be active. 
Glutathione may be transported into the mitochondria from the cytosol, or may be de novo 
synthesized in mitochondria.  
In contrast to mitochondria and the nucleus, the endoplasmatic reticulum is a 
compartment with a more oxidizing environment than the cytosol. The ratio of GSH/GSSG 
appears to range from 1:1 to 3:1 (64) which is very low compared to the overall ratio in the cell 
of  30:1 to 100:1. The more oxidizing environment of the endoplasmatic reticulum ensures 
proper protein folding and disulfide bond formation in proteins.  
Glutathione is also present in extracellular pools (78) in the concentration range of 1-10 
µM. This suggests that the extracellular surface of most cells is potentially more vulnerable to 
oxidants from extracellular exposure. There are several proposed physiological roles for 
extracellular glutathione. Extracellular glutathione functions in detoxication and protection of 
cells from chemical- and oxidant-induced injury, and it may control the extracellular oxidation-
reduction state and may thus contribute to the protection of cell membranes (92). Hwang and 
Sinskey (1991) (63) showed that cultured cells maintain their extracellular redox states and that 
there is a linear correlation between extracellular thiols and viable cell density. They found that 
thiol-disulfide ratios were an important component of the redox potential and that thiol release 
was a universal characteristic feature of cells in culture. But, very little information is available 
on the relative efflux rates of glutathione and cysteine and it is unclear whether the GSH/GSSG 
redox couple is equilibrated with other redox active components in extracellular fluids.  
An important function of extracellular glutathione is to serve as a source of cysteine in 
the overall sulfur amino acid balance. GSH cannot be broken down intracellulary and it must 
be released to be degraded by ecto-enzyme γ-glutamyltranspeptidase to yield cysteine. 
Cysteine is a critical amino acid for synthesis and function of many cellular proteins, and it is 
highly reactive so that only low concentrations of cysteine can be tolerated inside the cell. 
Thus, cysteine is transiently stored in cells as GSH in a less reactive form and one of the 
functions of extracellular glutathione is therefore to supplement the endogenous synthesis (7, 
28, 56, 57, 84). It is also used as a substrate for extracellular GSH-dependent enzymes (124), 
for protection of critical thiol groups of transporters and receptors present on the extracellular 
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surface of cells (126), for reduction of iron for iron absorption, for the reduction of disulfides to 
control mucus fluidity, and for the maintenance of other antioxidant systems (e. g. ascorbate). 
 
 
1.6  The Multiple Roles of Cysteine in Cells 
 
Thiols are organic compounds that contain the –SH functional group (called the thiol-, 
mercapto- or sulfhydryl group). Thiols, because of their ability to be reversibly oxidised, are 
recognised as key components involved in the maintenance of the redox balance. Thiol groups 
located in various molecules act as a redox sensitive switch and thereby provide a common 
target for a variety of reactive oxygen and reactive nitrogen species (95). The most abundant 
biologically occurring thiol is the amino acid cysteine together with its disulfide cystine. 
Extracellular cysteine is oxidized within minutes to cystine, the disulfide form of cysteine   
(Fig. 6).  
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Figure 6. Structure of cysteine (Cys) and its disulfide cystine (Cys-S-S-Cys) 
 
Cysteine´s ability to occur in up to 10 different sulfur oxidation states in vivo allows the 
formation of a range of cysteine modifications in peptides and proteins including thiols, 
thiolates, thiyl radicals, disulfides, sulfenic (RSOH), sulfinic (RSO2H) and sulfonic acids 
(RSO3H), disulfide-S-oxides and selenodisulfides. Each of these cysteine modifications has its 
own chemical and biochemical properties such as stability, redox behaviour, metal binding, 
acidity, nucleophilicity and catalytic activity. The chemical properties of the neighbouring 
amino acids have furthermore a strong impact on the behaviour and pH-dependence of these 
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cysteine modifications. This versatility enables cysteine to fulfill a wide range of different 
functions in proteins including disulfide formation, metal-binding, electron donation, 
hydrolysis, and redox-catalysis.  
Cysteine-based redox systems are exceptional since sulfur can participate in several 
mechanistically distinct redox-reactions. These reactions (Fig. 7) can be classified as 
thiol/disulfide exchange reactions (thioredoxin, Trx); electron transfer reactions (glutathione 
reductase, GR); thiol/thiyl hydrogen radical transfer reactions (in ribonucleotide reductase, 
RNRase); oxygen atom transfer reactions (in peroxiredoxins, NADH oxidase (Nox) and 
NADH peroxidase (Npx)); and different hydride transfer reactions (in Npx and glyceraldehyde 
3-phosphate dehydrogenase, GAPDH). 
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Figure 7. Oxidation states, properties, reactivity, and occurrences of different cysteine modifications in vivo. 
Oxidation states of sulfur are given for R in oxidation state +1 (Giles et al., 2003) 
  
Besides the role of cysteine in catalytic reactions, disulfide bonds play also an 
important role in determining the tertiary structure and the metabolism of proteins. Molecules 
containing cysteine are among the most easily metabolized compounds. They are easily 
oxidized by transition metals and participate in thiol-disulfide exchange reactions. The 
concentration of protein-sulfhydryl groups in cells and tissues is much higher than that of 
glutathione (134). These groups are present in proteins as thiols (-SH), disulfides (PS-SP) and 
mixed disulfides (PS-SG) when conjugated with GSH. Protein S-thiolation or dethiolation are 
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dynamic processes that are reversible and occur at different rates depending on the protein and 
nature of the thiol groups in the protein (39). The oxidation of protein sulfydryl groups to 
mixed disulfides is an early cellular response to oxidative stress (130). 
Cysteine and its disulfide form cystine also constitute an important extracellular thiol-
disulfide system (99), that have important role in the regulation of different cellular processes 
such as cell proliferation, differentiation and apoptosis (98). Despite the oxidizing nature of the 
extracellular environment, the presence of reduced thiol (-SH) groups may be supported and 
maintained on the cell surface by the specific cell surface microenvironment. Thiol containing 
substances like GSH, thioredoxin and glutaredoxin participate in the regulation of the redox 
state on the cell surface (110). 
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From the previous work of the group it was known that Burkitt lymphoma cells are 
highly sensitive to suboptimal grow conditions in vitro and grow very poorly when seeded in 
tissue culture at low cell density or at reduced serum concentration in the absence of irradiated 
fibroblasts (25, 45). In the absence of feeder cells the cells undergo apoptosis at low cell 
density. The high sensitivity towards induction of apoptosis is caused by increased oxidative 
stress at low as compared to high cell density. One limiting factor appeared to be the uptake 
capacity of B cells for cystine. Cystine uptake is the limiting step in the synthesis of 
glutathione, a central player in the antioxidant defense system of the cell. Feeder cells take up 
cystine from the medium, reduce it intracellularly and secrete the surplus as cysteine that can 
be efficiently taken up by cocultivated Burkitt lymphoma cells by the amino acid transport 
system with specificity for alanine, serine and cysteine (ASC-system). As similar observations 
have been made for murine B cells and mouse and human T lymphocytes, these findings 
suggested that one important factor in the network of regulation of apoptosis in the lymphoid 
system might be the uptake capacity for cystine.  
The murine and human amino acid uptake system for cystine has been cloned by Sato 
and Bannai in 1999 and 2000 (116, 117). It is an antiporter importing cystine in exchange for 
glutamate. It is a heterodimeric membrane protein consisting of two chains, xCT, specific for 
the cystine-glutamate antiporter, and 4F2heavy chain (4F2hc), a multifunctional protein present 
as the common chain in many different amino acid transport systems.  
The aim of this work was to express the cystine-glutamate antiporter ectopically in 
Burkitt lymphoma cells and to study (i) the susceptibility versus resistance of transfected cells 
to apoptosis induced by growth at low cell density and by depletion of glutathione; and (ii) to 
elucidate the nature of the pathway induced by overexpression of the xCT light chain that 
controls cell survival under non-permissive conditions. 
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3.1 Chemical reagents 
 
α-Thioglycerol    Sigma-Aldrich Chemie GmbH, Deisenhofen 
Acrylamide     Carl Roth & Co., Karlsruhe 
Agarose     Invitrogen Life Technologies, Karlsruhe 
Ampicillin     Merck KgaA, Darmstadt 
Bacto-agar     Difco Laboratories, Michigan, USA 
Bacto-yeast extract    Difco Laboratories, Michigan, USA 
Bacto-tryptone    Difco Laboratories, Michigan, USA 
DL-Buthionine -[S, R]-sulfoximine   Sigma-Aldrich Chemie GmbH, Deisenhofen 
DNA 1Kb Plus Ladder   Invitrogen Life Technologies, Karlsruhe 
RNA ladder 0.24-9.5 kb   Invitrogen Life Technologies, Karlsruhe 
dNTPs      GibcoBRL Life Technologies GmbH, Karlsruhe 
DNA linkers      New England Biolabs GmbH, Schwalbach 
Ethanol p.a.      Merck KgaA, Darmstadt 
Ethidiumbromide    Merck KgaA, Darmstadt 
Fetal bovine serum    Biochrom KG, Berlin 
      PAN, Biotech GmbH 
      Sigma-Aldrich Chemie GmbH, Deisenhofen 
      GibcoBRL Life Technologies GmbH, Karlsruhe 
LMP-agarose     MBI FERMENTAS, St. Leon-Rot 
L-glutamine     Invitrogen LifeTechnologies, Karlsruhe 
L-Pyruvate     Invitrogen LifeTechnologies, Karlsruhe 
Sulfosalicylic acid dihydrate   Sigma-Aldrich Chemie GmbH, Deisenhofen 
Mineral Oil     Sigma-Aldrich Chemie GmbH, Deisenhofen 
5, 5’-Dithio-bis (2-nitrobenzoic acid) Sigma-Aldrich Chemie GmbH, Deisenhofen 
β-NADPH tetrasodium salt   Sigma-Aldrich Chemie GmbH, Deisenhofen 
L-Cystine     Sigma-Aldrich Chemie GmbH, Deisenhofen 
Di-n-buthyl Phthalate    Sigma-Aldrich Chemie GmbH, Deisenhofen 
Phosphate Buffered Saline (tablets)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Phosphate Buffer Saline   Merck KgaA, Darmstadt
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Glutathione (reduced form)   Sigma-Aldrich Chemie GmbH, Deisenhofen 
Diethyl Ether p.a.    Merck KgaA, Darmstadt 
Penicillin-streptomycin   Invitrogen LifeTechnologies, Karlsruhe 
RPMI-1640 cell culture medium  GibcoBRL Life Technologies GmbH, Karlsruhe 
Puromycin     Sigma-Aldrich Chemie GmbH, Deisenhofen 
Hygromycin B    Invitrogen LifeTechnologies, Karlsruhe 
Propidium iodid    Sigma-Aldrich Chemie GmbH, Deisenhofen 
Annexin-V-FITC    BD PharMingen, Heidelberg, Germany 
 
3.2 Enzymes 
 
Glutathione reductase    Sigma-Aldrich Chemie GmbH, Deisenhofen 
from Baker’s Yeast (500 U) 
Bacterial Alkaline Phosphatase  GibcoBRL Life Technologies GmbH, Karlsruhe 
Klenow fragment    New England Biolabs GmbH, Schwalbach 
T4 DNA Ligase     New England Biolabs GmbH, Schwalbach 
Restriction endonucleases   New England Biolabs GmbH, Schwalbach 
      MBI FERMENTAS, St, Leon-Rot 
Pfu DNA polymerase    Promega Corp., Wisconsin, USA 
RED-Taq DNA polymerase   Sigma-Aldrich Chemie GmbH, Deisenhofen 
 
3.3 Antibodies 
 
The mouse monoclonal antibodies: 
anti-Bax YTH-2D2 (1:10000) Trevigen Inc. Gaithersburg, MD 
anti-Bcl-2 100/D5 (1:100)                 Novocastra, Dossenheim, Germany  
The rat monoclonal antibody: 
anti Bcl-w 16H12 (1:1000)  ALEXIS GmbH, Gruenberg, Germany 
The plyclonal goat antibodies: Anti-PUMA N-19 (1:100) , anti-Bid C-20 (1:1000) and anti-
Nbk/Bik N-19 (1:1000)                      Santa Cruz Biotechnology, Santa cruz, California 
The following antibodies were polyclonal rabbit antibodies used ina dilution 1:1000:  
Anti-Bak     Dako, Hamburg, Germany 
Anti-Bcl-x and anti-Bad   BD Transduction Laboratories, Heidelberg, Germany 
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Anti-Bim and anti-p53   BD PharMingen, Heidelberg, Germany 
Anti-β-actin     Sigma-Aldrich Chemie GmbH, Deisenhofen 
 
3.4 Radioactive Isotopes 
 
[α-32P] dCTP (3000 Ci/ mmol, 10m Ci/ ml)   Amersham Pharmacia Biotech,  
Freiburg, Germany 
L- [14C (U)] Cystine (250 mCi/ mmol/ 0.02 mCi/ ml)  Perkin Elmer Life Sciences, Inc., 
Boston, USA 
 
3.5 Disposables and Kits 
 
3MM-paper      Whatman Ltd., Kentucky, USA 
Cell culture plasticware    Greiner GmbH, Frickenhausen 
General laboratoryware    GLW GmbH, Würzburg 
DNA Midi/ Maxi kits     Qiagen GmbH, Hilden 
DNA gel extraction kit    Qiagen GmbH, Hilden 
PCR purification kit     Qiagen GmbH, Hilden 
Rneasy Mini/ Midi kit    Qiagen GmbH, Hilden 
Jet Star 2.0 Plasmid Purification kit   Genomed, Bad Oeynhausen 
Carboxylfluoroscein FLICA Apoptosis  ALEXIS GmbH, Gruenberg, Germany 
Detection Kit Caspase Assay  
Electroporation cuvettes, 4 mm   Bio-Rad Laboratories, München 
Oligonucleotides     Metabion, München 
Parafilm      Dynatech, Denkendorf 
Polypropilene tubes 15 ml, 50 ml   Becton-Dickinson GmbH, Heidelberg 
Centrifugation sampling tube    Bender & Hobein GmbH, Bruchsaal 
(0.4 ml, 46.8 mm x 5.7 mm with lid) 
Reactione vials 1.5 ml, 2 ml    Eppendorff-Nertheler-Hinz, Hamburg 
Readyprime TM II DNA labelling kit   Amercham Pharmacia Biotech, Freiburg 
Sephadex G-50 (NICKTM Column)   Amersham Pharmacia Biotech, Freiburg 
X-ray film (XAR5, BIOMAX.MS)   Eastman Kodak Co, New York, USA 
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3.6 Bacteria 
 
DH10B: E. coli strain obtained from Invitrogen GmbH, Karlsruhe. Used for the routine cloning 
steps of plasmid DNA. 
 
E.coli K12, GM 2163 (dam- and dcm – strain) used for maintaining unmethylated plasmid 
DNA, obtained from New England Biolabs GmbH, Schwalbach, Germany. 
 
3.7 Cell line 
 
HH514 is a human, EBV positive Burkitt’s Lymphoma cell line, a subclone of the P3HR-1 cell 
line.  
 
3.8 Stably transfected cell lines 
 
All transfections were performed using the BL cell line HH514 as a parental cell line. 
 
3.9 Parental cell line   
 
Name     Plasmid     Resistance 
 
HH514  AB1  m4F2hc-pREP7    Hyg 
HH514  AB2  IRES-m4F2hc-pREP7   Hyg 
HH514  AB3  IRES-EGFP-pINCO (control)  Pur 
HH514  AB4  mxCT-IRES-EGFP-pINCO   Pur 
HH514  AB5  mxCT-IRES-m4F2hc-pREP7  Hyg 
HH514  AB6  pREP7 + IRES-EGFP-pINCO (control) Hyg + Pur 
HH514  AB7  m4F2hc + IRES-EGFP-pINCO (control) Hyg + Pur 
HH514  AB8  mxCT-IRES-EGFP + pREP7 (control) Hyg + Pur 
HH514  H (1 and 2) hxCT-p141     Pur 
HH514  M (1 and 2) mxCT-p141 (control)    Pur 
HH514  141 (1 and 2) p141 (control)     Pur 
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3.10 Materials for cloning 
 
3.10.1 Oligonucleotides 
 
All oligonocletides were obtained from Metabion GmbH, Martinsried, Germany. 
 
MC 1: 5’ ATT TCA TTC GAA CGG AGA TCT TG 3’ (MC linker for cloning) 
MC 2: 5’ CTA GCA TGA TCT CCG TTC GAA TG 3’ (MC linker for cloning) 
 
hxCT 3.1: 5’GAG GGA ACG AGG AGG TGG AG 3’ (for the generation of a human xCT 
specific probe used in Northern Blots) 
hxCT 5.1: 5’GTG ATG ACG AAG CCA ATC CC 3’ (northern blot probe as above) 
 
m4F2 3.1: 5’ AGG CTG TCC AGG AAG GGC ACC 3’ (used for sequencing) 
h4F2 3.2: 5’ CCG TAC AGG CCT AGA AGT AA 3’ (used for sequencing) 
h4F2 3.3: 5’ GGT CCA GAA TGA CAC GGA TGC 3’ (used for sequencing) 
h4F2 3.4: 5’ ACC TTG ATC TTC ACC AGA CC 3’ (used for sequencing) 
h4F2 5.1: 5’ GAA GAT TTT GAC AGT CTC TTG C 3’ (used for sequencing) 
h4F2 5.2: 5’ CTG CAT GGT GAA GTC TTC C 3’ (used for sequencing)                                                    
h4F2 5.3: 5’ AGT CAT GCT GTG GGA TGA GTC C 3’ (used for sequencing) 
mxct 5.3: 5’ CAT TCT GGA GGT CTT TGG TCC 3’ (used for sequencing) 
hxct 5.5: 5’ GTG GAA CTC CTC ATA ATA CGC CC 3’ (used for sequencing) 
 
3.10.2 Linkers for cloning 
 
All linkers were ordered from New England Biolabs GmbH, Schwalbach, Germany.  
 
BclI linker  5’ d(pCTGATCAG) 3’ 
EcoRI linker 5’ d(pGGAATTCC) 3’ 
HindIII linker 5’ d(pCAAGCTTG) 3’ 
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3.10.3 Vectors used for cloning 
 
All basic vectors used for the cloning steps of both genes (human and mouse xCT) are 
listed: 
1) 141-pCAG-3SIP: eucaryotic expression vector carrying an IRES–puromycin 
phosphotransferase gene (gift from Timm Schroeder) (Fig. 8) 
2) pINCO: eucaryotic expression plasmid harbouring a retroviral packinging system, 
and conferring puromycin resistance (gift from P. G. Pelicci) (Fig. 9) 
3) pREP7: eucaryotic expression plasmid conferring hygromycine resistance 
(Invitrogen LifeTechnologies, Karlsruhe, Germany) (Fig. 10) 
4) pMC30: IRES containing vector (gift from Marcus Conrad ) 
5) pIRES2-EGFP: IRES-EGFP containing vector (Clontech, Heidelberg, Germany) 
6) pSPORT-mxCT: vector containing mxCT sequence (gift from S. Bannai) 
7) pSPORT-m4F2hc: vector carrying mouse 4F2hc gene (gift from S. Bannai) 
8) pBlueScript-hxCT: vector harbouring human xCT gene (gift from S. Bannai) 
Figures 8 ,9 and 10 are shown at the end of this chapter. 
 
List of intermediate and final clones generated in this work 
 
Intermediate clones 
 
1) pINCO-IRES-EGFP (introduction of IRES-EGFP in pINCO vector in order to generate 
the expression plasmid mxCT-IRES-EGFP-pINCO) 
2) IRES-m4F2hc-pREP7 (insertion of IRES 5´from m4F2hc for the generation of mxCT-
IRES-m4F2hc-pREP7 expression vector) 
3) pSPORT-mxCT-EcoRI linker (introduction of an EcoRI site 5´ from the mCXT ORF 
allowing the transfer of mxCT as an EcoRI fragment in p141-pCAG-3SIP and in 
pINCO-IRES-EGFP) 
4) pSPORT-mxCT-HindIII linker (insertion of a HindIII site for the transfer of mxCT in  
pREP7-IRES-m4F2hc to generate the expression plasmid mxCT-IRES-m4F2hc-
pREP7) 
5) p141-pCAG-3SIP-MC linker 
 28
MATERIALS 
 
 
Final expression plasmids used for transfection of HH514 cells 
1) m4F2hc-pREP7 
2) mxCT-pINCO 
3) mxCT-IRES-EGFP-pINCO 
4) mxCT-IRES-4F2hc-pREP7 
5) mxCT-pREP7 
6) mxCT-p141-pCAG-3SIP 
7) hxCT-p141-pCAG-3SIP 
 
All cloning steps are described in detail in chapter 5.4. 
 
 
 
3.10.4 Maps of vectors used for the expression of mouse and human xCT and 
mouse 4F2 hc 
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RsrII
BstEII
BsmBI
SexAI
BfrBI
NsiI
Ppu10I
ClaI
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BclI SphI
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BsaBI
SfiI
SapI
DrdI
BciVI
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SA
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Figure 8. Restriction map of 141 pCAG- 3 SIP (CAG = CMV, chicken beta actin, globin; 3 SIP = translational 
stop element in every possible ORF followed by IRES and puromycine phosphotransferase gene) 
 
 29
MATERIALS 
 
 
pINCO
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Figure 9. Restriction map of the pINCO vector (This plasmide carries retroviral packinging system: 5’LTR and 
3’LTR sequences (long terminal repeats) and conferring puromycin and ampicilin  resistances) 
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Figure 10. Restriction map of the pREP 7 vector (High-level of constituve expression is driven by CMV or RSV 
promoters. The Epstein-Barr Virus replication origin (oriP) and nuclear antigen (encoded by the EBNA-1 gene) is 
carried by this plasmid to permit extrachromosomal replication in human, primate and canine cells. This plasmid 
also carries the hygromycine B resistance gene.) 
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During this work the standard protein and molecular biology techniques were used (6, 
111), and described in following text. 
 
 
4.1 Culture of Bacteria 
 
Bacteria were cultured either on LB agar plates or in liquid LB medium in an incubator 
at 37°C overnight. Selection of transformed bacteria was achieved by adding the corresponding 
antibiotics. 
 
LB medium      LB agar    
20 mM MgSO4     20 mM MgSO4  
10 mM KCl      10 mM KCl  
1% (w/v) Bacto-Tryptone    1% (w/v) Bacto-Tryptone 
0.5% (w/v) Bacto yeast extracts   0.5% (w/v) Bacto yeast extracts 
0.5% (w/v) NaCl     0.5% (w/v) NaCl 
       1.2% (w/v) Bacto-agar 
 
4.1.1 Preparation of competent bacteria 
 
To increase the efficiency of plasmid DNA uptake (transformation), bacteria were 
treated with solution of di-valent cations. A LB plate was first inoculated with a probe from 
bacterial stock (XL-1 blue E. coli strain) and grown overnight at 37°C. A single colony was 
used to inoculate 2 ml of LB medium, which was then incubated overnight at 37°C in a loose-
capped vessel, with shaking. The following day, the entire overnight culture was used to 
inoculate 100 ml of LB medium containing 100mM KCl and 200mM MgCl2. Bacteria were 
grown at 37°C in a 1l flask, with shaking, until absorbance at 600 nm (A600) reached 0.4-0.55 
(approximately 2-4 hours). The bacterial pellets were collected by centrifugation on 4000 rpm, 
for 10 min., at 4 °C. The pellets were resuspended in 15 ml TFB1 buffer and incubated for 5 
min. on ice. After another centrifugation (4000 rpm/10 min./4°C) the pellet was resuspended in 
2ml of ice-cold TFB2 buffer. Aliquots of 200-300 µl bacteria were snap-frozen in dry ice and 
removed to storage at –80°C. 
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TFB1 
30 mM Potassium acetate 
50 mM MnCl2 
100 mM RbCl  
10 mM CaCl2  
15 % (w/v) glycerin  
Adjust to pH 5.8 with 0.2N acetic acid; sterile filter (0.2 µm) 
 
TFB2 
10 mM MOPS pH 7.0 
75 mM CaCl2  
10 mM RbCl  
15% (w/v) glycerin   
Adjust to pH 6.5 with 1M KOH; sterile filter (0.2 µm) 
 
4.1.2  Transformation of bacteria 
 
For sub-cloning and production of large amounts of cloned DNA, the Escherichia coli 
strain, DH5-α 10B was used. For transformation 1 ng to 0.1 µg of plasmid DNA in a 10 µl 
volume of ligation mixture was added to 50-100 µl of competent bacteria suspension and 
incubated on ice for 30 min. The bacterial cells were subjected to heat schock at 42°C for 90 
sec., before returning them on ice for another 2 min. 900µl of SOC medium (LB recovery 
medium) was added to the cells and incubated for 1 hour at 37°C to allow the cells to express 
resistance genes conferred by the plasmid. For routine transformations, 100 µl of suspension 
was plated onto LB-agar plates containing ampicillin and grown at 37°C overnight. 
 
4.1.3  Miniprep of plasmid DNA 
 
Plasmide DNA was purified using JETstar kit (GENOMED GmbH, Bad Oeynhausen 
Germany), according to the manufacturer’s protocol. Procedure is based on a modified 
alkaline/SDS method. High molecular weight chromosomal DNA is denaturated when cells are 
lysed at pH 12.0-12.6, whereas low molecular weight supercoiled plasmid DNA remains 
unaffected. Neutralisation of the pH in the presence of high salt concentrations subsequently 
precipitates chromosomal DNA, which then can be separated from the mixture. A single 
colony obtained from transformation bacteria was used to inoculate 2 ml of LB medium 
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containing the appropriate antibiotics (ampicillin), and incubated overnight in 20 ml loose-
capped tube with vigorous shaking at 37°C. The following day the bacterial pellet was 
collected by centrifugation at 14000 rpm for 1 min, and resuspended  in 200 µl of solution E1 
supplemented with RNAse by vigorous vortexing. Bacterial cells were lysed in alkaline lysis 
solution E2 (200µl) and cell debrises were precipitated with E3 solution (200 µl) and removed 
by centrifugation at 14000 rpm for 10 min. at room temperature. Plasmide DNA from the 
resulting supernatant was precipitated with 500 µl of isopropanol (centrifugation at 15000 rpm 
for 15 min at 4°C) and resuspended in 50 µl of TE buffer.  
 
Solution E1 (Cell Resuspending) 
50 mM Tris-HCl pH 8.0 
10 mM EDTA 
RNase 20 µg/ml 
 
Solution E2 (Cell Lysis) 
200 mM NaOH 
1% SDS (w/v) 
 
Solution E3 (Neutralization) 
3.1 M potassium acetate pH 5.5 
 
4.1.4 Maxi-prep of plasmid DNA 
 
Large quantities of plasmids were purified using Qiagen Maxi prep protocols based on 
modified alkaline lysis procedure. Plasmid DNA is recovered by running the bacterial lysate 
through an anion exchange column under appropriate low-salt and pH conditions. Following 
washing, the DNA can be eluted by a high-salt buffer. All steps have been done according to 
the manufacturer’s protocol. 
Briefly, a single colony was used to inoculate a starter culture of 2-8 ml of selective LB 
medium and incubated overnight at 37°C. The following day the starter culture was then 
diluted 1:500 into 100-300 of selective LB medium and grown overnight at 37°C with shaking. 
Bacterial cells were harvested by centrifugation, and were resuspended in 10 ml of chilled 
alkaline lysis solution I containing 100 µg/ml Rnase A. 10 ml of alkaline lysis solution II was 
added to the suspension and mixed gently by inverting. Following the incubation on ice and 
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centrifugation at 20000 rpm for 30 min. at 4°C, the supernatant was applied to a Qiagen 
column equilibrated with 10 ml of equilibration buffer and washed twice with 30 ml of wash 
buffer. The bound plasmid was eluated in 15 ml elution buffer and precipitated by adding 10.5 
ml (0.7 volumes) of isopropanol and resuspended in 300 µl of TE buffer. 
 
Equilibration buffer 
 
50mM MOPS pH 7 
750 mM NaCl 
15% ethanol 
 
Wash buffer 
 
50mM MOPS pH 7 
1M NaCl 
15% Ethanol 
 
Elution buffer 
 
50 mM Tris-HCl pH 8.5 
1.25 M NaCl 
15% Ethanol 
 
 
4.2 Molecular biology techniques 
 
4.2.1 Cloning of plasmid DNA 
 
Restriction digests were carried out according to the manufacturer’s instructions. In 
brief, for the cloning steps 10 µg of plasmid DNA were digested with 20 u of enzyme for 2 h at 
the given temperature in a final volume of 50 µl. In case of a double digest, the primary digest 
was precipitated with 2.5 volumes of 100% EtOH and 0.3 M NaCl. The DNA was recovered 
by centrifugation at 13000 rpm, 10 min, and 4°C. The pellet was washed with 70% EtOH and 
the DNA was briefly air-dried and resuspended in 1 x TE. After the second restriction digest, 
the DNA was either subjected to further modification, e.g. dephosphorylation, and then loaded 
on a LMP agarose gel. Electrophoresis on a LMP gel was performed on 70V (higher voltage 
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induces melting of a gel). Elution of DNA from LMP gel are described in the chapter 
“Isolation of DNA for cloning and analysis”. 
 
4.2.2  Dephosporylation of 5’ ends 
 
Deposphorylation of 5´ ends was performed to prevent religation of linearized vector 
with compatible cohesive ends. Following digestion, DNA fragments were incubated with 150 
u of bacterial alkaline phosphatase (BAP) for 1 hour at 65°C in final volume of 50 µl. 
 
4.2.3 Filling in DNA overhangs 
 
To enable the ligation of non-compatible ends, overhanging (sticky) ends were filled in 
to generate universally-compatible (blunt) ends. Linearized DNA was treated with Klenow 
DNA polymerase for 25 min at room temperature, as recommended by the manufacturer’s 
protocol. The reaction was stopped either by phenol treatment or by loading on a LMP agarose 
gel.  
 
4.2.4 Ligation of DNA ends /or with DNA linkers 
 
DNA fragments were ligated by using T4 DNA ligase (400000 u/ml) and 10 x ligase 
buffer (supplemented with 10 mM ATP). In all experiments phosphorylated linkers were 
purchased from Biolabs New England, Schwalbach, Germany. The concentration of the linkers 
was 0.4 µg/µl, and 1 µg for the vector. Ligations were performed overnight at 16°C. 
 
4.2.5 Hybridisation of complementary oligonucleotides 
 
For the production of double-stranded linker DNA, equimolar amounts of 5’ 
phosphorylated complementary oligonucleotides were mixed, heated to 95°C in a thermo-
mixer for 5 min, and then allowed to slowly cool to RT.  
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4.2.6 Polymerase chain reaction (PCR) 
 
The standard polymerase chain reaction (PCR) was performed essentially as 
recommended by the manufacturer. For standard (analytical) applications, Taq polymerase was 
used, whereas the proof-reading DNA polymerase, Pfu, was used for cloning purposes. The 
DNA template (20 ng) to be amplified was mixed with 20 µM of forward and reverse primers, 
0.5 mM dNTPs (dATP, dGTP, dCTP, dTTP), and 2.5 U Taq DNA polymerase in a volume of 
50 µl and 1 x polymerase buffer. PCR was performed in a thermocycler. The PCR cycles 
consisted of an initial denaturation step for 4 min at 95°C, followed by the amplification cycles 
(20 sec 95°C; 20 sec annealing temperature; 30 sec.-1min. elongation time at 72-73°C; 30-35 
cycles) and a final incubation time for 7 min at 72°C. The elongation temperature, and 
elongation time used was dependent on the DNA polymerase used (Taq polymerase 500 
bp/min at 72°C; Pfu polymerase has an optimal elongation rate of 500 bp/min at 73°C).  
 
4.2.7 Isolation of DNA for cloning and analysis 
  
The DNA PCR products and DNA fragments were isolated (purifed) by using a Qiagen 
quick protocol. The protocol combines convenience spin-column with selective binding 
properties of a uniquely-designed silica-gel membrane. DNA adsorbs to the silica-membrane in 
the presence of high salt concentration, while contaminants pass through the column. 
Impurities are efficiently washed away, and the pure DNA is eluated with Tris buffer or water. 
The procedure has been done according to the manufacturer’s protocol. For the PCR 
purification buffer PB (guanidine chloride and isopropanol) was used. Salts were washed away 
by the ethanol containing PE buffer. Elution of DNA provided by buffer EB or water with low 
concentration of salt and under basic conditions. 
Purification of DNA fragments also has been done by phenolisation, followed by 
ethanol precipitation. For purification of DNA, low melting type of agarose was used. A band 
of interest was removed form the gel and melted at 68°C in a 1.5 ml reagent tube. An equal 
volume of phenol (pH 8.0) was then mixed with the melted gel, before centrifugation at 15000 
rpm to remove protein contaminations. The resulting supernatant was repeatedly phenolised (2-
3 times) before precipitation and resupended in a suitable volume of TE buffer pH 8.0. 
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TE buffer 
10 mM Tris-HCl pH 8.0 
1 mM EDTA 
 
4.2.8 Generation of eucaryotic expression vectors for human and murine  xCT 
and murine 4F2hc 
 
1) Eucaryotic expression vector for m4F2 heavy chain (m4F2hc-pREP7) 
 
Vector pREP7 was digested with KpnI and NotI, dephosporylated with BAP and ligated with 
the m4F2 fragment isolated from pSPORT-m4F2 by KpnI and NotI. 
 
2) Eucaryotic expression vector for mxCT (mxCT-pINCO) 
 
Vector pINCO was digested with EcoRI and NotI, dephosporylated with BAP, and ligated with 
the mxCT ORF that was isolated from pSPORT-mxCT with the same enzymes. 
 
3) Eucaryotic pINCO-IRES-EGFP expression vector 
 
pIRES2-EGFP was digested with EcoRI and NotI in order to generate the IRES-EGFP insert 
that was subsequently inserted in pINCO linearized with the same enzymes (EcoRI, NotI). 
 
4) Eucaryotic mxCT-IRES-EGFP-pINCO expression vector 
 
pSPORT-mxCT was digested with HindIII, blunt-ended with Klenow, thereby generating a 
NheI site. This plasmid was ligated with an EcoRI linker in order to generate pSPORT-mxCT-
EcoRI linker. The coding region of mxCT, obtained by EcoRI digestion of pSPORT-mxCT-
EcoRI linker, was finally cloned in the EcoRI site of pINCO-IRES-EGFP. 
 
5) Eucaryotic mxCT-IRES-m4F2hc-pREP7 expression vector 
 
pREP7-m4F2hc was linearized with NheI, blunt-ended, and dephosporylated. The IRES 
sequence was excised from pMC30 by EcoRI digestion, blunt-ended, and inserted in the NheI 
digested, blunt-ended site of pREP7-m4F2hc. In parallel, pSPORT-mxCT was digested with 
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EcoRI, blunt-ended with Klenow, that will lead to an AseI site and ligated with a HindIII linker 
in order to generate the plasmid pSPORT-mxCT-HindIII linker. The mxCT open reading frame 
was isolated from pSPORT-mxCT-HindIII linker by HindIII digestion that was inserted in the 
HindIII site of pREP7-IRES-m4F2hc. The final vector was mxCT-IRES-m4F2hc-pREP7. 
 
6) Eucaryotic expression vector for mxCT (mxCT-pREP7 and mxCT-pINCO) 
 
6.1 mxCT-pREP7 
 
mxCT-pSPORT was grown in dam- bacteria (E. coli K12, GM2163, BioLabs, New England, 
Schwalbach, Germany) digested with BclI, filled-in with Klenow, digested with HindIII, and 
finally ligated in pREP7 previously digested with PvuII and HindIII. Resulting plasmid was 
mxCT-pREP7. BclI digestion was necessary to remove a first non-sense open reading frame in 
the 5’UTR. 
 
6.2 mxCT-pINCO 
 
A BclI linker was inserted in mxCT-pINCO (see also cloning step No. 2) after linearization 
with EcoRI, Klenow-treatment and dephosphorylation. After passaging in a dam- bacterial 
strain, the plasmid was digested with BclI, filled-in with Klenow polymerase, and religated. 
This step was necessary to remove a putative first non-sense open reading frame in the 5´UTR. 
 
7) Insertion of mouse xCT in the expression vector141pCAG-3SIP 
 
Firstly, mouse xCT-pSPORT clone was digested with BclI, blunt-ended, dephosphorylated and 
then ligated with an EcoRI linker. Subsequently, the HindIII site was converted to a NheI site 
(digestion with HindIII, Klenow-treatment and religation). Finally, murine xCT cDNA was 
transferred as a HindIII/NheI fragment in 141 pCAG- 3 SIP. The final plasmid was named 
mxCT-IRES-Pur-141 pCAG- 3 SIP. 
 
8) Cloning of human xCT into 141pCAG-3SIP (IRES-Puromycine) vector 
 
The synthetic linker MCa/b(MCa: 5’ ATT TCA TTC GAA CGG AGA TCT TG 3’ and MCb: 
5’ CTA GCA TGA TCT CCG TTC GAA TG 3’), harbouring EcoRI, BstBI, BglII sites, was 
cloned in the expression vector 141 pCAG- 3 SIP linearized with EcoRI and NheI. Human xCT 
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cDNA was isolated from pBlueScriptSK+ hxCT as a ClaI/BglII fragment and inserted in 141 
pCAG- 3 SIP + MC between the BstBI and BglII sites. The expression plasmid was, thus, 
referred as hxCT-IRES-Pur-141 pCAG- 3 SIP. 
 
 
4.3 Eucaryotic cell culture 
 
4.3.1 Cultivation of Burkitt’s lymphoma cells 
 
Cells were cultivated in suspension culture at 37°C and 6% CO2 under water saturated 
atmosphere. Optimal growth of HH514 was achieved at a density of 3 x 105. Cells were 
cultured in standard medium (see below) and routineously splitted at a ratio of 1:3 every third 
day.  
 
Standard cell culture medium 
RPMI 1640-medium 
10% FCS 
2 mM L-glutamine 
100 U/ml penicillin 
100 mg/ml streptomycin 
In some experiments medium was supplemented with 100µM α-thioglycerol and 1 mM 
sodium pyruvate. 
 
4.3.2 Assessments of cell number 
 
The number of living and dead cells in a given volume was calculated using Fuchs-
Rosenthal or Neubauer haemocytometer. 30 µl of cell suspension was mixed with an equal 
volume of 0.5% (w/v in PBS) trypan blue solution. By this method, dead cells can easily be 
discriminated from living cells by the blue staining of the cells due to leakage of the plasma 
membrane. Living cells are unstained.  
 
4.3.3 Cryo-conservation and thawing of eucaryotic cell(s) lines 
 
Stocks of cell lines can be stored for several years in liquid nitrogen. Cells were split 
1:1 with fresh medium one day before storage. Cells were collected by centrifugation (1500 
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rpm, 5 min.), the supernatant removed the cell pellet resuspended in storage medium 
(approximately 1x107 cells/ml),  and transferred as 1 ml aliquots in 1.5 ml cryotubes. Cells 
were firstly frozen overnight at –80°C before and then transferred in liquid nitrogen.  
Storage medium was: 10% RPMI 1640; 10% DMSO and 80% FCS. 
Cells were thawed in a waterbath at 37°C, immediately transferred to 10 ml RPMI 1640 
medium. Cells were collected by centrifugation at 1500 rpm for 5 min and resuspended in 3 ml 
of 10% RPMI 1640 medium supplemented with 100 µM α-thioglycerol and 1 mM sodium 
pyruvate. 
 
4.3.4 Stable transfection of BL cells 
 
For the production of stably expressing cell lines, expression plasmids were introduced 
into cell lines selected with the appropriate antibiotic for at least two weeks after transfection. 
To achieve optimal transfection efficiencies, cells were split 1:1 one day prior to transfection. 
Around 2x107 cells were used per transfection. 
Cells were collected by centrifugation (1500 rpm for 5 min) and resuspended at a 
density of 2 x 107 cells in 300 µl of RPMI 1640 medium. Cells were transferred to a 0.4 cm 
electroporation cuvette on ice, mixed with 20 μg of plasmide DNA, and electroporation was 
carried out at a voltage of 240 V and capacitance charge of 950 µF at room temperature. In 
case of integrating plasmids such as 141-pCAG-3SIPmxCT and 141-pCAG-3SIPhxCT, 
plasmid DNA was linearized prior to transfection. Immediately after electroporation, cells were 
resuspended in 3 ml of 10% FCS RPMI 1640 containing 100 μM α-thioglycerol and 3 mM 
pyruvate and cultivated in 6 well plates. Cells were recovered for 24 h. After one day, cells 
were splitted 1:3 and selection was started by adding the appropriate antibiotic (e.g. 
puromycine at final concentration 2 μg/ml). Proliferation of the cells was monitored 
microscopically and stably transfected cell lines were obtained usually within two weeks. 
 
4.3.5 Dilution experiments 
 
 To test for the capability of proliferation of untransfected or transfected HH514 cell 
lines dilution experiments were performed. Cells were seeded in 96 well plates at different cell 
densities and at a final volume of 200 µl per well. The initial cell concentration was 1x105 
cells/ml, and by serial dilution cells were diluted to a density of 97 cells/ml. In all experiments 
cells were cultured in RPMI 1640 medium, 2 mM glutamine and 5% FCS (PAN, Biotech, 
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GmbH, Germany). In some experiments medium was additionally supplemented with 100 µM 
α-thioglycerol and 1 mM sodium pyruvate. Outgrowth of the colonies was monitored by 
microscopic inspection up to 40 days post-plating. The colour change of the medium from red 
to yellow was used as an initial indication to monitor cell proliferation.  
 
4.3.6 BSO treatment 
 
In order to investigate the influence of glutathione depletion on the viability of 
untransfected and transfected HH514 cells, cells were treated with different concentrations of 
BSO ranging from 0, 5, 10, 20, 30, 50 to 100 µM. Cells were seeded at a concentration of 
1x105 cell/ml in final volume of 2-3 ml per well in 6 well plates in triplicates. The number of 
viable and dead cells was determined by the trypan blue exclusion method over period of 6-8 
days. Cells were cultured in RPMI 1640 medium, 2 mM glutamine and 10% FCS (Biochrom 
KG, Germany). 
 
4.3.7 Co-culture assay 
 
To investigate whether xCT-overexpressing cells could promote the outgrowth of 
vector-transfected cells under conditions non-permissive for the control cells, co-culture 
experiments were performed. xCT-overexpressing cells and control cells were seeded at a 
density 5x104 cells/ml each in six well plates in 2 ml of standard medium supplemented with 
10 µM BSO. As a control, cells from either cell line were seeded at densities of 5x104 cells/ml 
or 105 cells/ml. The number of viable cells and total cells was monitored over a period of 8 
days. 
 
 
4.4 Methods for the analysis of DNA, RNA and proteins 
 
4.4.1 Radioactive labelling of DNA fragments 
 
 The multi prime method (46, 47) was used for labelling of DNA fragments. Usually, 
30-50 ng DNA were labelled using the Redprime TM II randome prime labeling system 
(Amersham Biosciences UK, Buckinghamshire, England) and 50 µCi [α-32P]-dCTP (3000 
Ci/mmol, 10 mCi/ml), according to the manufacturer’s protocol. Non-incorporated nucleotides 
were separated from the labelled probe by using a Sephadex G-50 column (NICKTM Column, 
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Amersham Biosciences). The labelling products were measured using a bench-top radioisotope 
counter (Bioscan, Washington D. C., USA). Before hybridisation in church buffer, the probe 
was heat-denatured at 95°C, for 5 min. 
 
Church buffer  
200 mM NaH2PO4  
400 mM Na2HPO4
7% SDS (w/v) 
1 mM EDTA  
pH 7.1-7.2 
 
4.4.2 Isolation of total RNA 
 
 Total cellular RNA (of approximately 0.5-1 x 107 cells) was extracted by using RNeasy 
Mini and Midi kit (Qiagen, Hilden, Germany) according to the manufacturer’s specification. 
The cells were splitted one day before extraction. Total RNA was dissolved in 50-300 µl 
DEPC treated water (DEPC was added into water the day before in order to inhibit RNAse 
activity) and the samples were stored at –80°C. 
 
4.4.3 Northern blot analysis 
 
10 μg of total RNA was lyophilised in a speed vac (Speed Vac Concentrator SVC100H, 
Savant Instruments NC, Farmingdale; N. Y., USA), dissolved in 15 µl RNA loading buffer and 
incubated at 70°C for 10 min to minimize secondary structures. RNA was separated on a 1% 
agarose gel in the presence of 2.2 M formaldehyde in MOPS buffer overnight with a voltage of 
40 V. Upon separation, the amount of loading of the RNA samples was estimated by 
visualisation of the gels using a UV (254 nm) trans-illuminator. RNA was transferred to a 
Hybond-N+  membrane (Amersham Pharmacia Biotech) using 10 x SSC solution. The gel was 
placed on a glass plate covered with two Whatman filter papers (dipped in reservoirs with 10 x 
SSC solution) and overlaid with a Hybond-N+  membrane. The membrane was covered with 
several layers of blotting paper (“Zellstoff”) and RNA was transfered to the membrane by 
capillary forces. The transfer of the RNA was controlled by UV light. RNA was covalently 
linked to the membrane by baking the membrane at 80°C for 1 hour. Before hybridisation of 
the probe, the membrane was pre-hybridised at 65°C for 3 hours in church buffer. 
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Hybridisation was performed at 68°C overnight in 15-20 ml of fresh church buffer containing 
around 1x107 dpm of radioactively labelled probe. Membranes were washed twice for 15 
minutes at 68°C with 2 x SSC, 1% sodium dodecyl sulfate (SDS) and then twice for 10 
minutes at 68°C with 0.1 x SSC, 0.5% SDS. Membranes were then dried, and exposed to an X-
ray film (Kodak, BioMAx, U. S. A) usually over night at - 80°C. 
 
RNA loading buffer     1% Formaldehyde-agarose gel 
50% (v/v) formamide     2.2 M formaldehyde 
2.2 M formaldehyde     1 x MOPS buffer 
1 x MOPS buffer     1% (w/v) agarose 
50 µg/ml ethidium bromide 
0.2% (w/v) bromphenol blue 
 
20 x SSC      10 x MOPS    
3 M NaCl      0.4 M MOPS (free acid) 
300 mM Tris-sodium citrate/NaOH pH 7.0  100 mM Na-acetate 
10 mM EDTA/NaOH pH 8.0 
pH 7.0 (adjusted with 10 N NaOH) 
 
 
4.4.4 SDS-PAGE Electrophoresis 
 
Denaturing (SDS) polyacrylamide gel electrophoresis (PAGE) was performed 
essentialy as described previously (109). 10 µl of cell suspension (approximatelly10-30 µg of 
protein solubilised in SDS-PAGE loading buffer) were denaturated by boiling at 95°C before 
loading on a SDS-PAGE gel. Pre-stained markers (Bio-Rad Laboratories, Hercules, CA) were 
used to estimate the  molecular weight. The amount of acrylamide in the separating gel 
depended on the size of the proteins to be analysed usually ranging between 10- 15%. (106). 
Electrophoresis was performed at constant current of 30 mA/gel in 1 x SDS running buffer. 
After SDS-PAGE separation, gels were subjected for Western blotting. 
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Separating gel 15% (60 ml)    12.5 % (60 ml) Separating gel 12.5 % (60 ml) 
30 % Acrylamide 25 ml  30 ml  30 % Acrylamide 25 ml  
4 x Tris/SDS pH 8.8 15 ml  15 ml  4 x Tris/SDS pH 8.8 15 ml 
Aqua Dest. 20 ml   20 ml   Aqua dest. 20 ml  
10% APS 200 µl   200 µl  10% APS 200 µl  
TEMED 40 µl    40 µl  TEMED 40 µl    
    
       
4 x Tris/SDS pH 8.8 (500 ml)   4 x Tris/SDS pH 6.8 (100 ml)  
Tris 91 g       Tris 6.05 g 
SDS 2 g      SDS 0.4 g 
adjust to pH 8.8 with HCl    adjust to pH 6.8 with HCl 
 
10 x SDS-PAGE Running buffer 
0.25 M Tris-base 
2.5 M glycine 
0.5% (v/v) SDS 
 
4.4.5 Protein extraction and immunobloting 
 
 
After treatment under the respective conditions, cells were washed twice with PBS and 
lysed in buffer containing 10 mM Tris/HCl pH 7.5, 300 mM NaCl, 1% Triton X-100, 2 mM 
MgCl2, 5µM EDTA, 1µM pepstatin, 1µM leupeptin, and 0.1 mM phenylmethylsulfonyl 
fluoride. Protein concentration was determined using the bicinchonic acid assay (Pierce, 
Rockford, IL), and equal amounts of protein (20 µg per lane), were separated by SDS-PAGE. 
Immunoblotting was performed as described (149). Membranes (Schleicher & Schull, Dassel, 
Germany) were swollen in CAPS-buffer, and blotting was performed at 1 mA/cm2 for 1 hour in 
a transblot SD cell (Bio-Rad, Muenchen, Germany). The membrane was blocked for 1 hour in 
PBST (PBS, 0.05 % Tween-20) containing 3% non-fat dry milk and incubated with the 
primary antibody for 1 hour. After washing in PBST, the respective secondary antibodies 
conjugated to horse radish peroxidase (Promega, Madison, WI) were applied for 1 hour. 
Finally, the membrane was washed in PBST, and protein bands were detected using the 
enhanced chemiluminescence system (Amersham Buchler, Braunschweig, Germany). 
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CAPS buffer 
10 mM 3-[cyclohexylamino]propane-1-sulfonic acid, pH 11,10 
10% Methanol 
 
 
4.5 Biochemical methods 
 
4.5.1 Measurement of L-cystine uptake activity 
 
Uptake of cystine was measured by techniques essentially as described by Sagara et al., 
1993 (108, 109) and Novogrodsky et al., 1979 (101). About 2 x 106 cells were washed in PBS 
and resuspended in 0.125 ml of pre-warmed PBS containing 0.1% glucose and 0.01% Ca2+, 
Mg2. 125 µl of isotope labeled cystine (0.1 μCi/sample) (L- [14C (U)] Cystine (250 mCi/ mmol/ 
0.02 mCi/ ml) (Perkin Elmer Life Sciences, Inc., Boston, USA) uptake solution was added to 
the cell suspension, and suspension was incubated at 37°C. 100 µl aliquots were taken after the 
given time intervals and layered on a mixture of mineral oil and di-n-butyl phthalate 15:85 
(vol/vol; total 200 µl) previously put in a small plastic tube. After centrifugation at 13000 rpm 
for 10 sec in a microfuge, the tip of the tube containing the cell pellet was cut off, and the cells 
were solubilized in 200 µl of 0.5 M NaOH in a scintillation vial overnight at 37°C. Afterwards 
3 ml of scintillator liquid and 100 µl of Tris-HCL were added to the vials and the radioactivity 
was determined using a scintillation counter (Beckman Instruments, LIQUID SCINTILATION 
SYSTEM, LS 5000 TA, Fullerton, CA). To compare basic activity of uptake solution with 
uptake activity of the cells, 5 µl of isotope labeled uptake solution was taken and mixed with 
200 µl of 0.5 M NaOH for determination of specific activity.  
 
Uptake solution (for 10 samples)    1% (w/v) Ca2+, Mg2+  
 
50 µl [14C] Cyss (0.1 µCi/sample)    MgCl2 x 6 H2O 1 g 
5 mM Cyss 15 µl *      CaCl2 x 2 H2O 1.324 g 
5 x PBS 50 µl       dissolved in 100 ml of H2O  
10% (w/v) glucose 2.5 µl 
1% (w/v) Ca2+, Mg2+ 2.5 µl 
H2O 130 µl 
*5 mM Cyss dissolved in 0.05 M HCl and stirring for few hours at room temperature 
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4.5.2 Determination of intracellular glutathione  
 
Total cellular glutathione (GSH + GSSG) was measured as described by Bannai and 
Ishii, 1982 (15). This method is based on the glutathione reductase mediated catalytic reduction 
of 5,5’-dithio-bis-(2-nitrobenzoic acid) (Fig. 11) by glutathione (132).  
 
GSSG GSSGGR
NADPH NADP+
GSH
DTNB OD412
non-enzymatic
GR
NADP+ NADPH  
 
Figure 11. Glutathione reduction of DTNB by the glutathione reductase system 
 
Around 1 x 106 cells were collected by centrifugation (1500 rpm/ 10 min), washed with 
PBS and on ice for 30 min in 1 ml of 5% TCA (trichloracetic acid). This incubation step leads 
to extraction of total cellular glutathione. Subsequently, proteins and cellular debris was 
removed by centrifugation (1500 rpm, 5 min) and the supernatant including the glutathione 
was transferred to a fresh glass tubes. To remove TCA from the samples, ether extraction was 
performed. Ether saturated with 0.01 M HCl in volume four times bigger than TCA ressolved 
sample (1.5-2 ml), was added to a sample, vortexing and upper layer was removed by 
aspiration. The final step was incubation at 37°C for 10 min, to be sure that all ether were 
removed. 
For the glutathione determinations, a mixture of 1.2 ml of 0.2 M K-phosphate buffer, 
100 µl DTNB, 700 µl H2O, and 50 µl of glutathione reductase (from Baker’s Yeast (500 U), 
Sigma-Aldrich Chemie GmbH, Deisenhofen, Germany) was added to 500 µl of a sample. The 
reaction was started by adding of 50 µl NADPH (β-NADPH tetrasodium salt, Sigma-Aldrich 
Chemie GmbH, Deisenhofen, Germany) and the increase of DTNB reduction was measured at 
λ412 and two different time points (30 sec and 5 min). For the protein measurements, the 
protein pellet, obtained from the centrifugation step as described above, was dissolved in 500 
µl of 0.5 mM NaOH and the proteins extracted overnight. 100 µl of the extracts were used to 
determine the protein concentration according to the Lowry (89).  
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Reagents for glutathione determination: 
 
1) 0.2 M K-phosphate buffer (KH2PO4 + K2HPO4 = 2:5); 10 mM EDTA pH 7.2 
2) DTNB (5,5’-dithio-bis-(2-nitrobenzoic acid)) 10 mM (dissolved 4 mg in 1 ml of 0.1 M 
K-phosphate buffer; 5 mM EDTA) 
3) Glutathione reductase (GR) dilute 1 U/ 500 µl water final concentration 20 U/ml and 
for each sample 50 µl should be used 
4) NADPH 4 mM in water (0.2 µmol/50 µl), 50 µl per sample 
 
Solutions 2, 3, and 4 have to be freshly prepared. 
 
4.5.3 Determination of total thiol containing compounds 
 
4.5.3.1  Determination of total extracellular thiols 
 
For the determination of total thiols secreted into medium, a method previously 
described by Bannai and Ishii 1980 (13) was applied/used. The method is based on the 
chemical reduction of DTNB by thiol containing compounds that can be quantified by the 
increase of absorbance at 412 nm. About 2 x 106 cells were washed in serum free medium, 
resuspended in 2 ml of serum free medium and incubated for 2 hours at 37°C. Afterwards, cells 
were harvested by centrifugation (1500 rpm/5 min) and 1.2 ml of the supernatant was mixed 
with 1.2 ml 0.2 M K-phosphate buffer and 100 µl DTNB (0.4 mg/ml). The increase in 
absorbance was measured at 412 nm during 2 min and GSH was used as a standard. All 
solutions were prepared as described in chapter 5.6.2. 
 
4.5.3.2  Determination of acid soluble thiols 
 
 The procedure is based on the same protocol (13) used for the determination of secreted 
thiols (5.6.3.(b)). About 2 x 106 cells were cultivated for 24 hours in 20 ml (final concentration 
of the cells was 1x105cellc/ml) standard medium in the presence or absence of 50 μM BSO. 
600 µl of the cell-free supernatant were mixed with 200 µl 15% sulfo-salicylic acid and 
incubated on ice for 30 min in order to precipitate the proteins. Precipitated proteins were 
removed by centrifugation (10000rpm/ 10 min) and 700 µl of the supernatant were mixed with 
400 µl 0.6 M NaOH and 1.2 ml of 0.2 M K-phosphate saline. Finally, 100 µl DTNB (0.4 
mg/ml) were added to the mixture and the increase in absorbance was measured at 412 nm 
during a period of 2 min., GSH was again used as a standard. 
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4.5.4 HPLC determination of extra- and intracellular cysteine 
 
Determination of cysteine in cell culture supernatants was performed by the HPLC 
method described by Feussner et al. (49) with slight modifications. In brief, about 2 x 106 cells 
were washed, resuspended in 2 ml of serum free medium, and incubated for 2 hours at 37°C.  
Cells were collected by centrifugation and 100 µl of the supernatant were mixed with 100 µl 
2M borate buffer (containing 5 mM Na2EDTA, pH 10.05) and 100 µl SDBF (7-fluoro-benzo-
2-oxa-1,3-diazole-4-sulfonate) (1mg/ml in borate buffer) and incubated at 60°C for 60 min. 
The reaction was performed without any reducing agent to measure the free reduced cysteine 
only. The reaction was stopped by incubation on ice for 5 min. 200 µl of HClO4 containing 
0.5M EDTA were added to precipitate proteins. The sample was centrifuged and 50 µl of the 
supernatant were applied on a HPLC column (Separation column - LiChroCART 250-4 and 
precolumn -LiChrospher 60 RP-select B [5 µM], MERCK KGgA (Darmstadt, Germany); 
Beckman detector System Gold, Pump Model 126 and Beckman counter Autosampler System 
Gold 508). The mobile phase consisted of a 30 mmol/l ammonium-formiate – 40 mmol/ 
ammonium-nitrate buffer (pH 3.65) and acetonitrile (95 + 5, by vol) at a flow rate of 1 ml/min. 
The column effluent was monitored by fluorescence detection (Fluorescence Detector RF 
10Axl (Shimadzu, Japan)) with an excitation wavelength of 385 nm and an emission 
wavelength of 515 nm. 
For the determination of intracellular cysteine levels, cell pellets were resuspended and 
sonified by adding 20 µl of tri-n-butylphosphine for 30 min at 4°C, deproteinized using 
HCLO4 and centrifuged again. 100 µl of the supernatant was mixed with 250 µl of 2M borate 
buffer and thiol groups were derivatized using SBDF. HPLC was performed as described 
above. 
 
 
4.6 FACSTM-Analysis 
 
FACS analysis was used to measure the percentage of dead cells in some of 
experiments. Cells were stained with PI (propidiumiodide) in PBS. About 3-5x105 were 
collected by centrifugation at 1500 rpm for 5 min and resuspended in 200-500 µl of FACS 
buffer (PBS with 2% FCS) including PI at a final concentration of 2 µg/ml. Data were 
evaluated in a FACS-Scan, Cell Quest Software (Becton-Dickinson, Heidelberg, Germany). 
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4.7 Apoptotic assays 
 
4.7.1  Measurement of cell death by Annexin-V-FITC and propidium iodide 
staining 
 
Cell death was determined by staining cells with annexin-V-FITC and counterstaining 
with PI. Annexin-V-FITC binds to phosphatydilserine (PS) on the outer side of the plasma 
membrane. PI is excluded by cells with intact membranes. PI positivity is therefore a sign of 
necrosis, whereas positive for annexin-V, but negative for PI are generally defined as apoptotic 
(138). Cells were washed twice with cold PBS and resuspended in buffer (10 mM N-(2-
hydroxyethyl)piperazin-N’-3(propansulfonicacid)/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM 
CaCl2 ). Next, 5 µl of annexin-V-FITC (BD PharMingen, Heidelberg, Germany) and 10 µl PI 
(20 µg/ml, Sigma-Aldrich) were added. Analyses were performed using a FACScan and 
CellQuest analysis software (Becton Dickinson, Heidelberg, Germany). 
 
4.7.2 Assessment of genomic DNA fragmentation by flow cytometric 
measurement of nuclear DNA content 
 
To measure genomic DNA fragmentation, nuclear DNA content was determined by 
flow cytometry. 2x105 cells were pelleted in a 96 well U-bottom plate and fixed in 200 µl of 2 
%  (vol/vol) formaldehyde in PBS on ice for 30 min. After fixation, DNA was precipitated 
with 100% Et-OH for 15 min., pelleted and resuspended in PBS containing RNAseA (40 
µg/ml). Following incubation at 37°C for 30 min, the pellet was resuspended in 200 µl of 
propidium iodide (PI) (50 µg/ml) and incubated overnight in the dark at 4°C. Nuclear DNA 
fragmentation was quantified by flow cytometric determination of hypoploid DNA. Data were 
collected and analysed using  FACScan flow cytometer and CellQuest analysis software 
(Becton Dickinson, Heidelberg, Germany). Nuclei displaying a hypodiploid, sub-G1 DNA 
content were identified as apoptotic. Cell debris, characterized by low forward and side scatter 
values, was excluded from the analysis. 
 
4.7.3 Detection of active caspases 
 
Active caspases were determined by the FLICA Apoptosis Detection Kits (Alexis 
GmbH, Gruenberg, Germany) according to the manufacturer’s protocol. The methodology is 
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based on the covalent binding of a fluorochrome-labelled inhibitor of caspases (FLICA) to the 
active site (43). These inhibitors (VDVAD-AFC for caspase 2; DEVD-AFC for caspase 3; 
IETD-AFC for caspase 8 and LEHD-AFC for caspase 9) are cell permeable and non-cytotoxic. 
The number of cells with active caspase was determined by FACScan flow cytometer using 
CellQuest analysis software (Becton Dickinson, Heidelberg, Germany). FITC-labelled FLICAs 
were used for staining and positive cells were measured in the FL-1 channel. 
 
4.7.4 Determination of the mitochondrial membrane potential 
 
Cells were collected by centrifugation at 1500 rpm for 5 min, and the mitochondrial 
membrane potential was determined by staining the cells with 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethyl-benzimidazolycarbocyanin iodide (JC-1; Biotium, Inc. Hayward California) as 
described by von Haefen et al., 2004 (141). 2x105 cells were resuspended in 500 µl PBS 
containing  JC-1 at a final concentration of 2.5 µg/ml, incubated for 30 min at 37°C and 
moderately shaken. Cells were washed and resuspended in 200 µl PBS. The mitochondrial 
membrane potential was measured by flow cytometry using a FACScan (Becton Dickinson, 
Heidelberg, Germany) equipped with CellQuest software. Data are presented as percentage of 
cells with lowered membrane potential (ΔΨm). 
 
4.7.5 Determination of intracellular reactive oxygen species (ROS) levels 
 
Dichlorodihydrofluorescein diacetate (H2DCFDA) (Molecular Probes) was used to 
detect the generation of reactive oxygen intermediates. H2DCFDA is a nonpolar compound that 
is converted into a nonfluorescent polar derivative (H2DCF) by cellular esterase after 
incorporation into cells. H2DCF is membrane impermeable and rapidly oxidized to the highly 
fluorescent 2,7-dichlorofluorescein (DCF) in the presence of intracellular ROS . 4x105 cells 
were incubated with 5 µM H2DCFDA for 30 min at 37°C. Following the incubation time cells 
were washed and resuspended in 200 µl PBS. The number of cells with the higher levels of 
intracellular ROS was determined by FACScan flow cytometer using CellQuest analysis 
software (Becton Dickinson, Heidelberg, Germany) and were measured in the FL-1 channel. 
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5.1  Strategies for the stable overexpression of human and murine 
xCT chains in the BL cell line HH514 
 
Several cloning strategies, including different eucaryotic expression systems, were 
established in order to achieve stable overexpression of the human cystine-glutamate-antiporter 
(xc- system) in the BL cell line HH514.  
 
5.1.1  Initial strategy for cloning of murine xCT and 4F2hc in the expression 
plasmids pINCO and pREP7 
 
Initially, the idea was pursued to express both polypeptide chains, xCT and 4F2 heavy 
chain (4F2hc), either independently in two different episomal vectors encoding different 
antibiotic genes, or both chains as a bicistronic message consisting of murine xCT and 4F2hc 
(or GFP) separated by an internal ribosomal entry site (IRES) in one vector. 
 
a) For independent expression of xCT and 4F2hc, two different episomal vectors, pINCO 
and pREP7 encoding puromycine and hygromycine resistance genes, respectively, were 
used, as described in MATERIALS (Chapter 3, figures 9 and 10). Murine xCT was 
cloned into pINCO expression vector conferring puromycine resistance (pINCO-
mxCT) and murine 4F2 heavy chain was cloned into pREP7 expression vector 
conferring hygromycine resistance (pREP7-4F2hc). 
 
b) An IRES was used for several approaches: (i) expression of both chains in one vector 
(pREP7-mxCT-IRES-m4F2hc), (ii) to monitor xCT expression by a reporter gene such 
as EGFP (pINCO-mxCT-IRES-GFP), or (iii) to produce stably xCT expressing cell 
lines by using the selectable marker gene puromycine phosphotransferase. A schematic 
diagram of the translation of the bicistronic RNA is presented in figure 12.  
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Figure 12. Schematic diagram of the translation of a bicistronic mRNA. The internal ribosome entry site 
(IRES) permits a protein of interest and an antibiotic resistance gene or fluorescent protein used as selection 
marker to be translated from the same mRNA. IVS = synthetic intron. 
 
The HH514 BL cell line was transfected with the following plasmids: pREP7-m4F2hc, 
pINCO-mxCT, pINCO-mxCT-IRES-GFP, pREP7-mxCT-IRES-m4F2hc. Transfected clones 
were selected by puromycine and/or hygromycine and maintained under selection pressure. 
However, very soon it became obvious that it was not possible to establish stably expressing 
cell lines by using the pINCO expression plasmids and its derivatives. Cells transfected with 
pINCO-mxCT-IRES-EGFP could be selected with puromycine, however, EGFP expression 
was transient and only high during the first two weeks after transfection. EGFP expression 
finally disappeared, presumably as a result of silencing of the promoter. 
Stably transfected cell lines could be obtained with clone pREP7-mxCT. Four 
independent clones were selected and maintained under hygromycine selection, but Northern 
blot analyses showed that murine xCT was only weakly expressed in HH514 cells (data not 
shown). These experiments prompted us (i) to use a vector with a hybrid CMV-chicken β-actin 
promoter that is known to show no or little silencing (150), and (ii) to use a bicistronic 
expression vector that allows selection for expression of xCT.  
 
5.1.2 Final strategy for cloning of murine and human xCT light chain in 
141pCAG-3SIP and stable expression of xCT in HH514 
 
Since its discovery as a surface antigen in lymphocytes (59), 4F2 heavy chain was 
found to be present in all established human tissue culture cell line tested and in most 
malignant human cell lines (20, 38, 60, 105, 140). The expression of 4F2hc was tested in 
several different cell lines by northern blot experiments revealing that 4F2hc is ubiquitously 
expressed in all tested cell lines (Fig. 13). This indicates that the critical determinant of 
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expressing system xc- is the expression of xCT light chain, and that 4F2 expression does not 
limit cystine-glutamate-antiporter activity.  
 
4F2hc
28S
18S
 
 
Figure 13. Expression of human 4F2 heavy chain in different B cell lines. Northern blot revealing ubiquitous 
expression of 4F2hc (marked with an arrow) in different cell lines: 1-A1; 2-Raji; 3-BL-29; 4-LCL 1.24; 5- 
LCL1.26; 6-HH514; 7-Akata; 8-BL41; 9-BL41-P3HR1; 10-BL41-95.8. Lower panel is the Et-Br control of the 
agarose gel. 
 
 
Therefore, further work was focused on expression vectors expressing xCT only. An 
alternative strategy was designed to establish cell lines stably expressing xCT light chain using 
the non-episomal eucaryotic expression vector 141pCAG-3SIP. This vector was chosen for 
two reasons. Firstly, the hybrid CMV-chicken β-actin promoter driving expression of the gene 
of interest is known to be a strong promoter that is not prone to silencing in mouse ES cells and 
transgenic mice, and secondly, the puromycine phosphotransferase gene is expressed from an 
IRES allowing selection of xCT expression by puromycine. As no antibody is available to 
monitor expression of xCT, this indirect selection strategy turned out to be mandatory.  
Human and murine xCT light chain cDNAs were cloned in 141 pCAG-3SIP and 
transfected in HH514. The following clones were used: 
 
1) hxCT-IRES-Pur-141 pCAG-3SIP 
2) mxCT-IRES-Pur-141 pCAG-3SIP 
3) 141 pCAG-3SIP was used as an empty vector control  
 
Transfected clones were selected by puromycine at a final concentration of 2 µg/ml and 
maintained under selection pressure. At least three independent clones per transfection were 
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selected. Stably transfected cell lines were obtained after two weeks. Northern blot analyses of 
total RNA isolated from control cells (empty vector transfected cells) and xCT-overexpressing 
cells were performed to study expression levels of xCT. To study expression of human xCT, a 
specific probe (1.4 kb) was generated by PCR using the primers hxCT3.1 and hxCT5.1 (see 
Materials). To detect murine xCT by northern blotting, a probe was isolated from pSPORT-
mxCT by XhoI and BamHI digestion. Strong hybridisation signals were obtained 
corresponding to bicistronic human xCT-IRES-puromycine  (Fig. 14a and 14b) and bicistronic 
murine xCT-IRES-puromycine (Fig. 14c) mRNAs of 2.7 kb each. As expected, no signals were 
observed  in control cells. After long exposure, a weak signal corresponding to the endogenous 
xCT mRNA of 12 kb became visible (Fig. 14b).  
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Figure 14. Overexpression of human and murine xCT in HH514. Northern blot revealing hxCT (a and b) and 
mxCT expression (c) in BL cells. Two representative cell clones transfected with human (lanes 3 and 4 in a and b) 
and murine xCT (lanes 2 and 3 in c) show high overexpression of xCT (marked with an arrow) in contrast to cells 
transfected with the empty vector (lanes 1 and 2 in a and b, lane 1 in c). Panel (b) is a long exposure of (a) to 
visualize the low level of endogenous xCT expression (arrowhead). 
 
 
5.2 Phenotype of xCT overexpression in HH514 cells 
 
5.2.1 Cystine uptake activity in cells overexpressing xCT 
 
L-cystine uptake activity was measured in control and xCT transfected cells to confirm 
that overexpression of xCT leads to enhanced expression of a functional protein and thus, to 
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increased uptake activity. Figure 15 shows a time course of L-cystine uptake (0.1 μCi/sample) 
in non-transfected cells, empty vector transfected cells, and hxCT-overexpressing cells for the 
indicated time intervals (1, 2, and 3 minutes). L-cystine uptake was linearly increasing in 
overexpressing cells during the period of 3 minutes and remained unchanged in control cells 
(Fig. 15).  
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Figure 15. Overexpression of xCT promotes specific L-cystine uptake. Uptake of radioactively labelled L-
cystine was measured in non-transfected cells (?), empty vector transfected cells (?), and hxCT-overexpressing 
cells (?) for the indicated time intervals. The data represent mean values of two independent experiments with 
duplicate measurements +/- standard deviation and are presented as nmol L-cystine/mg of protein. 
 
 
L-cystine uptake in xCT-overexpressing cells was dramatically increased as compared 
to control cells (Fig. 15 and Table 2). 
 
 
Table 2 Time course of L-cystine uptake in xCT-overexpressing and control cells 
Sample    1 minute  2 minutes  3 minutes 
Non-transfected cells   0.203 ± 0.025  0.203 ± 0.025  0.213 ± 0.057 
Empty vector transfected cells  0.183 ± 0.047  0.423 ± 0.075  0.347 ± 0.015 
xCT transfected cells    2.44 ± 0.08  4.14 ± 0.23  6.16 ± 0.509 
Values are given as nmol L-cystine/mg of protein ± S.D. 
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To verify that L-cystine has in fact been taken up by the cystine-glutamate antiporter 
system, uptake of L-cystine was measured in the presence of the substrate L-glutamate that 
efficiently blocks L-cystine uptake when present in high concentrations. As shown in figure 16, 
transport of L-cystine in control and xCT-overexpressing cells was significantly inhibited by 
2.5 mM L-glutamate.  
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Figure 16. Overexpression of xCT promotes specific cystine uptake. To evaluate the specificity of cystine 
uptake through the cystine-glutamate antiporter, L-cystine uptake was inhibited by glutamate, a specific inhibitor 
of cystine uptake by xCT. Measurements were performed in the absence (filled bars) or presence (empty bars) of 
2.5 mM glutamate (Glu) within 1 minute of incubation. A fivefold reduction of specific L-cystine transporter 
activity could be observed in xCT-overexpressing cells in the presence of 2.5 mM glutamate. A clear decrease of 
L-cystine uptake was also noticed in empty vector-transfected cells. Data are presented as mean value of two 
independent experiments with duplicate measurements +/- standard deviation, presented as nmol L-cystine/ mg of 
protein/ min. 
 
 
In the absence of excess L-glutamate, the activities of L-cystine uptake in xCT-
overexpressing and vector-transfected cells was 2.93 ± 0.18 and 0.163 ± 0.021 nmol L-
cystine/min/mg protein, respectively. In the presence of 2.5 mM L-glutamate, uptake of L-
cystine was decreased to 0.52 ± 0.11 in xCT-overexpressing cells and to 0.0373 ± 0.002 nmol 
L-cystine/min/mg protein in vector-transfected cells corresponding to an inhibition of 83% and 
77%, respectively. 
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5.2.2 Determination and evaluation of the proliferation behaviour of HH514 cells 
 
From previous work in our laboratory (45) it has been known that BL cells are highly 
sensitive to suboptimal growth conditions. BL cells readily undergo apoptosis when seeded e.g. 
at reduced serum concentration or low cell density (non-permissive conditions). 
Supplementation of the growth medium with thiol containing compounds such as α- 
thioglycerol or dithiothreithol (DTT) in the presence of oxygen scavengers like sodium 
pyruvate (26) and the metal chelator bathocuproine sulfonate (BCS), efficiently prevented 
apoptosis under non-permissive conditions. In addition to the cell density, the batch of serum 
plays also an important role in defining the growth conditions of the cells. Antioxidants, free 
thiol groups, and/or trace elements (selenium, copper) in the serum are deemed to be the most 
critical factors affecting the survival and proliferation of the cells. The experiments in which 
the permissive and nonpermissive conditions for proliferation and survival of BL cells had 
been initially defined, had been performed in our lab about 10 years ago. Unfortunately, the 
batches of serum that had been used to define nonpermissive and permissive conditions in the 
papers of Falk et al. (1993, 1998) (44, 45) and Brielmeier et al. (1998, 2001) (25, 26) were no 
longer available. It was thus necessary to test a number of sera and to identify a serum which 
recapitulates the features that had been described by Falk et al. and Brielmeier et al. before. 
Nine sera from different suppliers were tested at different concentrations of serum (1, 2, 4, 6, 8 
and 10%) for their supportive effect on survival and proliferation of HH514 cells. Additionally, 
all experiments were performed in the presence or absence of 100 µM α-TG and pyruvate. 
Cells were seeded in a 96 well plates at serial dilutions ranging from 100,000 cells per ml to 
100 cells per ml in total volume of 200 µl per well. Cell survival was monitored by the medium 
colour change (acidification due to production of lactate) from red to yellow, three weeks after 
plating. All sera tested supported survival and proliferation more efficiently than the previously 
used batch. For the experiments, serum “PAN 7” was chosen as it did not maintain cell growth 
of HH514 cells at a cell density of less than 6000-3000 cells/ml at a concentration of 10%. As 
shown in figure 17, cells could easily survive and proliferate at low cell density when cultured 
in medium containing 100 µM α- thioglycerol plus pyruvate and BCS (Fig. 17a; e.g. 100 
cells/ml), whereas they were not capable of proliferating and died at a cell concentration of 
about 6000 cells/ml in the absence of supplements (Fig. 17b). 
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Figure 17. Supplementation of growth medium with α-thioglycerol allows BL cells to grow at low cell 
density. Three weeks after seeding, cell proliferation and survival were monitored by the medium colour change 
from red to yellow. Red medium colour indicates no proliferation (no production of lactate and pyruvate) whereas 
yellow colour indicates proliferation of HH514 cells during the given time period. In growth medium 
supplemented with α-thioglycerol, pyruvate, and BCS, cells were able to proliferate even at low cell density (100 
cells/ml), (a) whereas medium without supplements was unable to support cell proliferation at low cell density. In 
this experiment the critical cell concentration was 6000 cells/ml (b). 
 
 
 
5.2.3  Growth conditions of xCT-transfected HH514 cell clones 
 
In order to examine whether overexpression of human and murine xCT allows BL cells 
to grow at low cell density, cells were plated in standard RPMI medium containing 10 % FCS 
(PAN 7) without supplements in 96 well plates at serial dilutions ranging from 100,000 cells 
per ml to 100 cells per ml.. Three weeks after plating, survival could easily be monitored by the 
medium colour change from red to yellow, as depicted in figure 18. The critical cell density for 
survival and proliferation of empty vector-transfected cells and non-transfected cells (the 
parental HH514 cell line) was between 100,000 and 50,000 cells per ml (Fig. 18a and 18b). 
Overexpression of human and murine xCT in BL cells supported cell growth at densities of 
about 6000 cells per ml (Fig. 18c and 18d). 
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Figure 18. Overexpression of human and murine xCT allows BL cells to grow at low cell densities. Cell 
proliferation and survival could easily be monitored by the medium colour change from red to yellow three weeks 
after seeding. Empty vector-transfected cells (a) and non-transfected cells (b) were not able to survive and 
proliferate at a high cell density (100,000 cells/ml), whereas cells overexpressing human xCT (c) and murine xCT 
(d) were able to proliferate at a density of 6000 cells/ml. 
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5.3 Oxidative stress-mediated cell death induced by glutathione 
depletion  
 
To investigate whether xCT overexpression and, as the consequence, higher uptake of 
the cystine allows BL cells to survive and proliferate under limiting GSH conditions, xCT-
overexpressing cells and control cells were treated with buthionine sulfoximine (BSO), a 
specific inhibitor of γ-glutamyl-cysteinyl-synthetase, the enzyme that catalyses the first and 
rate-limiting step in GSH synthesis (54). BSO thus causes rapid depletion of intracellular GSH.  
 
5.3.1 BSO is not a substrate for the cystine-glutamate antiporter 
 
To investigate the possibility that BSO, due to its structural similarity with glutamate, 
might be a potential substrate for the cystine-glutamate antiporter, we had to rule out the 
possibility that the growth promoting effect of xCT overexpression is due to the export of BSO 
rather than due to the increased L-cystine uptake. L-cystine uptake activity was measured in 
xCT-overexpressing cells and control cells in the absence and presence of 5 mM BSO. No 
influence of BSO on the L-cystine uptake activity was observed in both cell lines (Fig. 19).  
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Figure 19. BSO is not a substrate for xCT. L-cystine uptake activity was measured in the absence (filled bars) 
and presence (empty bars) of BSO. No difference in xCT activity was observed in xCT-overexpressing and 
vector-transfected cells at a BSO concentration of 5 mM. 
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5.3.2 Survival and proliferation of glutathione-depleted cells  
 
5.3.2.1  BSO inhibits survival and proliferation of non-transfected cells, but not 
of xCT-overexpressing cells  
 
To investigate whether xCT overexpression allows BL cells to proliferate under 
limiting GSH conditions, xCT-overexpressing cells and vector-transfected control cells were 
treated with different concentrations of BSO (0, 5, 10, 20, 30, 50 and 100 μM) over a period of 
8 days. Cell viability was monitored by Trypan Blue exclusion. Overexpression of xCT-light 
chain strongly supported cell growth even in the presence of 100 μM BSO (Fig. 20a), whereas 
control cells died at 5 µM BSO (Fig. 20b) during the first 48 hours of treatment. These data 
show that increased uptake of L-cystine renders cells more resistant to GSH depletion. 
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Figure 20. Impact of different concentrations of BSO on viability and proliferation of xCT-overexpressing 
BL cells and vector-transfected control cells. In xCT-overexpressing and vector-transfected control cells, cell 
numbers were determined by trypan blue exclusion over a period of 8 days in the presence of different 
concentrations of buthionine sulfoximine (BSO), a specific inhibitor of glutathione synthesis. Dose dependent 
impairment of proliferation of xCT-overexpressing BL cells in the presence of 5 to 100 µM BSO (a). Survival of 
xCT-overexpressing cells was supported up to a concentration of 100 µM BSO, whereas vector-transfected cells 
died at concentrations of 5 µM and above (b). 
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5.3.2.2 The glutathione level is not critical for cell survival and proliferation of 
xCT-overexpressing cells  
 
The availability of cysteine is the rate-limiting step for the synthesis of glutathione 
(GSH), the major cellular antioxidant and scavenger of hydroxyl radicals, peroxides and lipid 
peroxides inside the cell (19). Having shown that xCT overexpression supports cell growth of 
HH514 cells at 100 µM BSO, it was important to answer the question whether xCT-
overexpressing cells will show higher levels of intracellular glutathione than control cells under 
BSO treatment.  
To this end, total GSH levels were determined in xCT-overexpressing and control cells 
after 24 hours in the absence or presence of different BSO concentrations (0, 5, 10, 20, 30 50, 
and 100 µM) (Fig. 21). As presented in figure 21, no marked difference in GSH levels between 
xCT-overexpressing cells and control cells could be detected despite the fact that 5 µM BSO 
induced apoptosis in vector-transfected control cells, but not in xCT-overexpressing cells. The 
absolute values are presented in Table 3. 
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Figure 21. Glutathione levels are strongly decreased in hxCT-overexpressing cells and vector-transfected 
control cells in the presence of BSO. Total cellular glutathione levels were measured in hxCT-overexpressing 
(filled bars) and vector-transfected cells (empty bars) after cultivation of cells for 24 hours in the absence of BSO 
and in the presence of different BSO concentrations. Glutathione levels were strongly decreased in both cell lines 
treated with different BSO concentrations. These data rule out the possibility that a treshold level of GSH is 
decisive for cell survival. The data represent mean values of three independent experiments with duplicate 
measurements ±SD and are shown as nmol of total glutathione/ mg of protein. 
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Table 3 Glutathione levels in xCT-overexpressing and control cells in the absence or presence 
of different concentrations of BSO 
Sample    xCT-overexpressing cells   control cells 
BSO (µM)  
0    4.15 ± 1.90    3.28 ± 0.72 
5    0.69 ± 0.07    0.643 ± 0.046 
10    0.0975 ± 0.0451    0.183 ± 0.028 
20    0.273 ± 0.238    0.383 ± 0.118 
30    0.234 ± 0.188    0.178 ± 0.033 
40    0.277 ± 0.081    0.17 ± 0.011 
50    0.136 ± 0.103    0.120 ± 0.104 
100    0.123 ± 0.074    0.0967 ± 0.085 
Values are given as nmol of total glutathione/mg of protein ± S.D. 
 
This finding was confirmed by HPLC analysis revealing that the GSH peak has 
disappeared in control as well as xCT-transfected cells after BSO treatment (Fig. 22).  
 
 
Figure 22. HPLC chromatogram for intracellular cysteine and glutathione. HPLC chromatogram of xCT-
overexpressing cells (xCT) and vector-transfected cells (control) in the absence (- BSO) and presence of 10 µM 
BSO (+ BSO). In xCT-overexpressing (xCT) and vector-transfected cells (control), the intracellular glutathione 
level is similarly high in untreated (upper part) and similarly low in BSO-treated cells (lower part). 
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These data strongly suggested that, to sustain cell survival, xCT overexpression does 
not increase the GSH levels above a critical threshold. Therefore, another mechanism than an 
increase in GSH level must be responsible for the supportive effect on cell survival and 
proliferation at low GSH concentration.  
 
5.3.3 xCT overexpression induces secretion of cysteine 
 
Since intracellular GSH levels in xCT-overexpressing and vector-transfected control 
cells were unchanged after BSO treatment, intra- and extracellular total mercaptan levels were 
determined in untreated cells and cells treated with BSO. 
 
5.3.3.1 xCT overexpression increases the intracellular cysteine levels  
  
Intracellular cysteine levels were determined by HPLC in untreated cells and cells 
treated with 30 µM BSO for 24 and 48 hours. As shown in figure 23a, in the absence of BSO 
xCT-overexpressing cells exhibited significantly higher levels of intracellular cysteine (4.96 ± 
0.65 nmol/mg) than control cells (0.69 ± 0.97nmol/mg). In the presence of 30 µM BSO, 
intracellular cysteine levels in xCT-overexpressing cells were not changed after 24 hours and 
were even higher (7.92 ± 0.42) after 48 hours. Intracellular cysteine levels in the control cells 
remained unchanged.  
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Figure 23a. Increased L-cystine uptake results in higher intracellular cysteien levels. Intracellular cysteine 
levels were determined in xCT-overexpressing cells and vector-transfected control cells that were either treated 
for 24 and 48 hours hours with 30 µM BSO (empty bars) or were left untreated (filled bars). xCT-overexpressing 
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cells have significantly higher levels of total mercaptans than vector-transfected control cells. The data represent 
mean values of two independent experiments with duplicate measurements ± SD. 
5.3.3.2 Extracellular levels of secreted mercaptans are strongly increased by xCT 
overexpression 
 
A dramatic difference between xCT-overexpressing and vector-transfected controls 
cells was found when extracellular total mercaptan levels were compared (Fig. 23b).  
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Figure 23b. High levels of total extracellular mercaptans are secreted from xCT-overexpressing cells. hxCT-
overexpressing and vector-transfected control cells were treated with 50 µM BSO for 24 hours (empty bars) or left 
untreated (filled bars) and were plated in serum-free medium at a density of 2 x 106/ml. Even after BSO treatment 
high amounts of extracellular mercaptans are secreted from xCT-overexpressing cells but not from vector-
transfected control cells. The data represent mean values of three independent experiments with duplicate 
measurements ± SD.  
 
 
xCT-overexpressing cells secreted high amounts of total mercaptans (22.3 ± 3.73 µM), 
whereas the levels secreted by vector-transfected control cells were by more than an order of 
magnitude lower (0.661 ± 0.187 µM). In xCT-overexpressing cells, the extracellular total 
mercaptan levels were slightly reduced after BSO treatment, but the huge difference between 
xCT-overexpressing cells (15.4 ± 7.15 µM) and vector-transfected control cells (0.407 ± 0.135 
µM) was still apparent. 
To rule out the possibility that the strong increase in total mercaptans secreted into the 
medium is the consequence of increased cell death, the percentage of dead cells was 
determined in xCT-overexpressing and vector-transfected control cells under the same 
experimental conditions that had been used for the determination of extracellular mercaptans. 
The percentage of dead cells was determined by FACS analysis (PI staining) or by trypan blue 
exclusion. No difference in the number of dead cells could be observed in hxCT-
overexpressing untreated and BSO treated as well as in non-treated vector-transfected control 
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cells (data not shown). As expected, the number of dead cells was high in control cells treated 
with BSO. The increase in the percentage of dead cells did not lead to an increase in the levels 
of total secreted mercaptans.  
 
5.3.3.3 The majority of small thiol containing compounds in the medium is  
bound to proteins 
 
Small thiol compounds such as glutathione, cysteine and homocysteine are present in 
plasma in two different forms: (i) to a major extent as small molecules in form of free thiols or 
mixed disulfides present in the acid-soluble fraction, and (ii) to a lesser extent as protein-bound 
fraction. We next asked whether the majority of the thiols is present in the acid-soluble or 
protein-bound fraction. 
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Figure 24. Extracellular thiols are mainly bound to serum proteins. Determination of thiol levels from the 
supernatant of xCT-overexpressing cells and control cells in medium containing 10% FCS without (a) and with 
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acid precipitation (b) revealed that elevated levels of mercaptans are secreted by xCT-overexpressing cells (a), and 
that the majority of these mercaptans is bound to serum proteins (b).  
To address this question, the level of total mercaptans determined without and with 
acidic precipitation of proteins were compared. This experiment showed that small mercaptans 
are mainly bound to serum proteins or proteins secreted into the medium by the cells, mostly to 
albumin (95). Without acidic precipitation, high levels of secreted mercaptans were observed in 
the culture medium of xCT-overexpressing cells (Fig. 23b and 23a). With acid precipitation 
(Fig. 23b) the difference in total secreted mercaptans was much lower but still significant. This 
indicates that the majority of small thiols is bound to free SH-groups of proteins present in the 
serum.  
 
5.3.3.4 The secreted extracellular mercaptan is predominantly cysteine 
 
HPLC analysis was performed to determine which type of mercaptan(s) is responsible 
for the dramatic difference in total secreted mercaptans of xCT-overexpressing cells versus 
empty vector-transfected control cells. As shown in figure 25, large part of the mercaptans 
secreted by xCT-overexpressing cells was cysteine regardless whether the cells had been 
treated with 50 µM BSO for 24 hours or had been left untreated. In contrast, in the supernatant 
of vector-transfected control cells L-cysteine was hardly detectable by HPLC analysis, 
regardless whether the cells had been treated with BSO or had been left untreated.  
 
 
Figure 25 xCT-overexpressing cells secrete cysteine. HPLC chromatogram of the medium of xCT-
overexpressing cells (xCT) and vector-transfected cells (control) in the absence (- BSO) and presence of 50 µM 
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BSO (+BSO). hxCT-overexpressing cells, treated with BSO or left untreated, secrete cysteine. No extracellular 
mercaptan was found in the supernatant of vector-transfected control cells.  
 
Under the HPLC conditions used, cysteine was the only secreted mercaptan. The 
concentration of L-cysteine was about 30 µM in the medium of xCT-overexpressing cells with 
or without BSO treatment as determined by HPLC analysis. This value corresponds very well 
to the concentration of total extracellular mercaptans determined by the DTNB method in 
serum-free medium (see Fig. 23b). 
 
5.3.3.5 In a coculture, xCT-overexpressing cells support the growth of control 
cells at conditions non-permissive for control cells 
 
To test whether xCT-overexpressing cells may provide a “feeder-like” effect on control 
cells by supplying them with cysteine, coculture experiments were performed (Fig. 26). 
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Figure 27. Coculture experiment: xCT-overexpressing cells support the growth of vector-transfected 
control cells at conditions non-permissive for control cells. xCT-overexpressing cells and vector-transfected 
control cells were seeded in a coculture, at a density of 5x104 cells/ml each in medium containing 10 µM BSO 
(?). As controls, xCT-overexpressing cells and vector-transfected control cells were seeded separately at 5x104 (? 
hxCT; ? control) and 1x 105 cells/ml (? hxCT; ? control). 
 
xCT-overexpressing cells and vector-transfected cells (control cells) were seeded, 
together in medium containing 10 µM BSO at a density of 5x104 cells/ml each. This cell 
density and BSO concentration are non-permissive for vector-transfected control cells. xCT-
overexpressing and control cells, seeded, distinctly, at densities of 5x104 cells/ml or 105 
cells/ml served as controls. The number of viable and total cells was monitored over a period 
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of 8 days. xCT-overexpressing cells were capable of proliferating at either cell concentration, 
whereas control cells alone died under these conditions. When both cell types were 
cocultivated, however, no cell death was observed and the cell number increased with the same 
kinetics as in cultures containing xCT-overexpressing cells only. This strongly argues that the 
xc- system-mediated supply of cysteine from xCT-overexpressing cells can rescue control cells 
from cell death induced by 10 µM BSO. 
 
5.3.4 Mode of the cell death induced by BSO  
 
The next question was whether treatment of cells with BSO provokes apoptosis or 
necrosis. xCT-overexpressing and vector-transfected control cells were treated with 10 µM 
BSO over a period of 2 days and analysed for intracellular ROS levels, annexin-V and 
propidium iodide (PI) staining, genomic DNA fragmentation, caspase-2, 3, 8 and 9 activation, 
and for the change of the mitochondrial membrane potential. hxCT-overexpressing and vector-
transfected cells that had been treated with 10 µM BSO in medium supplemented with 100 µM 
α-TG and 3 mM sodium pyruvate served as additional controls.  
 
5.3.4.1 BSO-induced formation of ROS is decreased in xCT-overexpressing cells 
as compared to control cells  
 
To address the question whether increased levels of intracellular ROS are responsible 
for cell death induced by BSO, cells were stained with the fluorescent dye H2DCFDA. 
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Figure 27. Reduced formation of intracellular ROS in xCT-overexpressing cells upon BSO treatment. BSO 
(10 µM) treatment  for 48 hours induces higher production of intracellular ROS in vector-transfected (empty bars) 
compared to xCT-overexpressing cells (black bars). 
 
H2DCFDA is intracellulary converted into the nonfluorescent polar derivate H2DCF 
that is rapidly oxidized to the highly fluorescent dye DCF in the presence of the intracellular 
ROS. xCT overexpresing cells and vector-transfected cells were treated with 10 µM BSO for 
48 hours or left untreated. As shown in figure 27, under BSO treatment the level of ROS 
generated in the vector-transfected cells increased markedly compared with xCT-
overexpressing cells.  
 
5.3.4.2 BSO-treated cells die by rapid apoptosis or necrosis 
 
To study the mode of cell death after BSO treatment, Annexin-V-FITC and PI staining 
were quantified. Generally two distinct ways of cell death are discriminated: necrosis and 
apoptosis. Necrosis is a passive process, occurring upon tissue injury or after accumulation of 
toxic reagents within a cell. The damaged cell is enlarged, plasma membrane disrupts, and 
cytosolic components are released into the extracellular space. In contrast, apoptosis or 
programmed cell death, is an active process characterized by a variety of morphological 
features, including changes in the plasma membrane such as loss of membrane asymmetry and 
blebbing associated with membrane inversion and exposure of phosphatidylserine, cell 
shrinking, chromatin condensation, and chromosomal DNA fragmentation. Changes in the 
plasma membrane are among the earliest features of cells undergoing apoptosis. In apoptotic 
cells, the membrane phospholipid phosphatidylserine (PS) is translocated from the inner to the 
outer leaflet of the plasma membrane, while in normal viable cells, PS is located on the 
cytoplasmic surface. Annexin V is a Ca2+-dependent phospholipid–binding protein that has 
high affinity for PS, and binds to apoptotic cells with exposed PS. Annexin V-FITC is used to 
quantitatively determine the percentage of cells undergoing apoptosis. Propidium iodide (PI) is 
used to distinguish viable from nonviable cells. Viable cells with intact membrane exclude PI, 
whereas membranes of dead and damaged cells are permeable for PI.  
Cells which stained neither positive for Annexin-V nor PI represent viable cells. As 
already shown in figures 20a and 20b and also documented in figure 28, viability of hxCT-
overexpressing cells decreased to a much lesser extent after 24 or 48 hours of BSO treatment 
(Fig. 28a), whereas the vast majority of empty vector-transfected cells started to die within 48 
hours of BSO treatment (Fig. 28b). As shown in figure 28b, control cells could be rescued from 
BSO-induced cell death also by α- thioglycerol (100µM) and pyruvate treatment. 
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Figure 28a. Percentage of viable hxCT-overexpressing cells after 24 and 48 hours of 10 µM BSO treatment 
Cells which stained neither positive for Annexin-V nor PI were used to quantitatively determine the percentage of 
viable cells. hxCT overexpressing cells were treated with 10 µM BSO, 100 µM α-TG, BSO and α-TG together, or 
left untreated during 24 hours (empty bars) and 48 hours (black bars). Viability of hxCT-overexpressing cells was 
not affected by BSO treatment. 
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Figure 28b. Percentage of viable empty vector-transfected cells after 24 and 48 hours of 10 µM BSO 
treatment Cells which stained neither positive for Annexin-V nor PI were used to quantitatively determine the 
percentage of viable cells. Viability was determined after 24 hours (empty bars) and 48 hours (black bars) 
culturing with 10 µM BSO, 100 µM α-TG, BSO and  α-TG, or without any treatment. Viability of the control 
cells decreased after 48 hours of BSO treatment, whereas medium supplementation with α-TG, protect cells from 
BSO induced cell death. 
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Positivity for Annexin-V-FITC is a characteristic feature of apoptosis (low right 
quadrant, Fig. 29 and 30), while positivity for PI (upper left quadrant, Fig. 29 and 30) indicates 
membrane damage and a necrotic type of cell death. Cells that stain positive for both Annexin 
V-FITC and PI are either in the end stage of apoptosis, undergoing necrosis, or are already 
dead. Only moderate amounts of dead cells undergoing apoptosis-like and necrosis-like death 
are visible in hxCT-overexpressing cells after 48 hours without (Fig. 29 upper panel) and with 
BSO treatment (Fig. 29 lower panel). xCT-overexpressing cells are virtually resistant to cell 
killing induced by 10 µM BSO (Fig. 28a and 29). In contrast, BSO treatment of empty vector-
transfected cells for 48 hours resulted in a substantial increase in necrosis-like cell death (Fig. 
30 lower panel), while apoptotic cell death, as determined by Annexin-V-FITC positivity and 
PI negativity, did not increase. BSO-induced necrosis-like cell death was associated with 
genomic DNA fragmentation (see figures 31a and 31b).  
 
 
 
 
Figure 29. Annexin-V/PI staining of hxCT-overexpressing cells either left untreated (upper panel) or treated with 
10 µM BSO for 48 hours (lower panel). 
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Figure 30. Annexin-V/PI staining of empty vector-transfected cells either left untreated (upper panel) or treated 
with 10 µM BSO for 48 hours (lower panel). 
 
 
5.3.4.3 xCT-overexpression or α-TG treatment protects cells from BSO-induced 
genomic DNA fragmentation 
 
Measurement of DNA fragmentation showed no significant difference in DNA 
fragmentation of xCT-overexpressing cells, within 24 and 48 hours of 10 µM BSO treatment 
(Fig.31a).On the other hand, empty vector-transfected cells (control cells) (Fig. 31b) after 48 
hours of BSO treatment showed increased DNA fragmentation to 28% of the total cell 
population. In the conditions where medium was supplemented with α- thioglycerol (100µM) 
and pyruvate, the empty vector transfected cells were resistant to BSO induced cell death, and 
the percentage of the apoptotic cells were the same as in the control. 
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Figure 31a. Percentage of hxCT-overexpressing cells showing hypoploid DNA under BSO treatment. xCT-
overexpressing cells were treated with 10 µM BSO, 100 µM α-TG, BSO and α-TG, or left untreated for 24 hours 
(empty bars) and 48 hours (black bars). No significant DNA fragmentation was obtained under BSO treatment 
neither after 24 nor after 48 hours. 
 
0
5
10
15
20
25
30
35
co
ntr
ol
co
ntr
ol+
BS
O
co
ntr
ol+
alp
ha
TG
co
ntr
ol+
alp
ha
TG
+B
SO
D
N
A
 fr
ag
. (
%
 h
yp
op
lo
id
y)
24 hours 
48 hours
 
Figure 31b. Percentage of empty vector-transfected cells showing hypoploid DNA under BSO 
treatment. Empty- vector transfected (control) cells were cultured during 24 hours (empty bars) and 48 hours 
(black bars) with 10 µM BSO, 100 µM α-TG, both together BSO and α-TG or left untreated. DNA fragmentation 
increased after 48 hours of BSO treatment, whereas α-TG medium supplementation protected cells from BSO 
induced apoptosis and no DNA fragmentation was obtained. 
 
 
5.3.4.4 xCT overexpression protects cells from BSO-induced caspase activation 
 
The molecular hallmark of apoptosis, is the activation of caspases (131), a cascade of 
proteolytic enzymes. These enzymes participate in a series of reactions that are triggered in 
 74
RESULTS 
 
 
response to proapoptotic signals and result in the cleavage of protein substrates involved in the 
transmission of signals causing cell death and the disassembly of the cell. Caspases are 
synthesized as inactive zymogens and must undergo a process of activation during apoptosis. 
To examine whether caspases are activated under BSO treatment, the cells were stained with 
fluorochrome-labelled peptides (FLICAs) specifically binding the activated forms of caspase 2 
(VDVAD-AFC), caspase 3 (DEVD-AFC), caspase 8 (IETD-AFC) and caspase 9 (LEHD-
AFC). Binding was evaluated by flow-cytometry. Analysis of caspases 2, 3, 8 and 9 (Fig. 32) 
activation showed that all four caspases were activated in empty vector-transfected cells 
(empty bars) after 48 hours of 10 µM BSO treatment, while hxCT-overexpressing cells (black 
bars) did not show any caspase activity after 48 hours BSO treatment. 
 
 
Figure 32. xCT overexpression protects HH514 cells from BSO-induced caspase activation. xCT-
overexpressing cells (black bars) and vector-transfected control cells (empty bars) were treated with 10 µM BSO 
(+BSO) for 48 hours or left untreated. Caspases 3 staining is exemplarily presented in (A). The quantitative 
evaluation of the FACS-staining for caspases 2, 3, 8 and 9 is presented in (B). 
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5.3.4.5  xCT-overexpression protects cells from BSO-induced mitochondrial cell 
death  
 
One of the early features of BSO-induced cell death is the disruption of the 
mitochondrial membrane potential. To ask whether xCT-overexpression affects the 
mitochondrial membrane potential of BSO-treated cells, the cells were stained with the cationic 
mitochondrial dye JC-1. JC-1 looses its red fluorescence in mitochondria with low membrane 
potential. The number of cells with lowered mitochondrial membrane potential ΔΨm was 
determined by flow cytometry. As shown in figure 33, xCT overexpression protected HH514 
cells efficiently from breakdown of the mitochondrial membrane potential induced by 
treatment of the cells with 10 or 50 µM BSO for 48 hours. 
 
 
Figure 33. xCT overexpression protects HH514 cells from BSO-induced breakdown of the mitochondrial 
membrane potential. The number of cells with low ΔΨm was determined by FACS analysis (A). A quantitative 
evaluation of the data is presented in (B). BSO treatment abrogates the mitochondrial membrane potential of 
control cells (empty bars) but not of xCT-overexpressing cells (black bars). 
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5.3.4.6 Overexpression of xCT does not alter the expression of Bcl-2 and Bcl-2 
family members 
 
Bcl-2 and its family members act primarly at the site of mitochondria controlling 
mitochondrial membrane potential and release of pro-apoptotic factors into the cytosol. 
Susceptibility to apoptosis is determined to a large extent by the balanced interplay of pro- and 
anti-apoptotic members of Bcl-2 family. To study a putative impact of xCT-overexpression on 
the expression of p53, the antiapoptotic proteins Bcl-2 and Bcl-xL, and Bcl-w and the 
proapoptotic family members Bax, Bak, Bid, Bim and Nbk/Bik, western blot analysis was 
performed. As shown in figure 34, no difference could be detected in xCT- versus vector-
transfected cells. 
 
Figure 34. Overexpression of xCT does not affect the expression of proteins that regulate cell death in 
mitochondria. Western blot analysis of the expression of p53, and pro- as well as antiapoptotic members of the 
Bcl-2 family that regulate cell death at the mitochondria. 
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6.1 Small thiol-containing compounds promote survival and 
proliferation of normal and malignant cells 
 
The identification of compounds that promote cell survival may provide useful tools for 
deciphering fundamental mechanisms by which cells live or die and also may give rise to 
compounds of potential use in clinical application. It has long been known that proliferation of 
murine normal B cells and leukemic cell lines is dependent on thiol-containing compounds 
(61). The reason for the requirement of thiol-containing compounds is the limited uptake 
capacity of the cells for cystine (68). It has been shown in our laboratory that human BL cells 
are equally dependent for their survival and proliferation on thiol-containing compounds, such 
as α-thioglycerol, 2-ME and dithiothreithol (DTT) that are added to the medium in conjunction 
with scavengers of oxygen radicals (44). BL cells have a high propensity to undergo apoptosis 
when seeded at low cell density in normal medium, but can be single-cell cloned either when 
thiol-containing compounds are added or when they are cocultured with irradiated fibroblasts 
as feeder cells (44, 45). Irradiated fibroblasts protect BL cells from apoptosis through secretion 
of a survival and proliferation-promoting activity which was soluble and labile and has been 
identified as cysteine (45). They are capable to take up cystine from the medium, reduce it 
intracellularly and secrete cysteine. Different groups have shown that proliferation of T- cells 
also requires a “small thiol compound” provided by activated macrophages or dendritic cells 
(123) that has been identified as cysteine and/or thioredoxin (4). Moreover, thioredoxin has 
been identified as a growth factor of Adult-Leukemia virus (ATLV-1)- transformed human T 
cells as well as of EBV immortalized human B cells (145).  
The requirement for thiol-containing compounds is not restricted to B and T 
lymphocytes. Neuronal cells also depend on cysteine that is secreted by glial cells (109) for 
their proliferation and survival. 
Generally, cells that are deficient in the capacity of cystine uptake, such as B and T 
lymphocytes and neurons, are dependent on thiol-containing compounds that are added to the 
medium or provided by cocultured fibroblasts, astrocytes, glia cells, macrophages or dendritic 
cells that are able to take up cystine efficiently and may provide it to their neighbouring cells as 
secreted cysteine. 
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One mechanism of the growth-promoting effect of 2-ME on mouse lymphoma cells, 
that is operating even if the medium has been completely oxidized, was proposed by Ishii et al. 
(67). The chemical reaction of 2-mercaptoethanol with cystine produces a mixed disulfide of  
2-ME and cysteine. The mixed disulfide is taken up by the cells via a transport system for 
bulky amino acids shared with methionine. Within the cell, the mixed disulfide is rapidly 
reduced and 2-ME exported into the medium where it initiates another round of reaction with 
cystine. As the supply of cysteine is the rate limiting step for the synthesis of glutathione, 
cysteine is rapidly incorporated into glutathione. 2-ME thus maintains a shuttle that guarantees 
a steady supply of cysteine for the cells (67). It is still unresolved as to whether the 
proliferative effect of cyst(e)ine is entirely mediated by a change in intracellular glutathione or 
is dependent on the reaction of thiols with extracellular receptors and the maintenance of an 
intra- and extracellular redox balance.  
To examine whether the restricted capacity for cystine uptake is the cause for the high 
sensitivity of BL cells to apoptosis, and to study the role of cystine uptake for the regulation of 
proliferation and apoptosis, we cloned the human and murine xCT-light chain, the component 
of the dimeric cystine glutamate antiporter conferring substrate specificity, and established 
stably xCT-overexpressing cell lines. We hypothesized that xCT overexpression would enable 
the cells to cover their intracellular cystine/cysteine supply by themselves, to use the cysteine 
for glutathione synthesis and thus to rescue cell survival and proliferation under non-
permissive conditions. 
 
6.1.1 Overexpression of xCT increases cystine uptake and compensates for the 
addition of exogenous thiol-containing compounds 
 
The aim of this project was to investigate the impact of increased availability of L-
cysteine on cell survival and proliferation. Due to their growth and proliferation behaviour, 
EBV-positive BL group I cell lines (i.e. BL lines that have retained the in vivo phenotype of 
BL cells in vitro)  were considered most suitable to address this issue (44, 45). One of the 
reasons for the sensitivity of BL cells to apoptosis seems to be their limited ability to take up 
cystine from the medium (45). The BL cell line HH514 was selected because of its ability to be 
efficiently transfected by electroporation (26). The human and murine xCT-light chain was 
cloned onto an eucaryotic expression vector and transfected into the BL cell line HH514. Thus, 
a cell line was established that stably expresses the light chain xCT of the heterodimeric 
cystine glutamate antiporter (xc- system). Since the second component of the xc- system, 4F2 
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heavy chain, is constitutively expressed, it was sufficient to transfect the light chain xCT in 
order to achieve increased L-cystine uptake. xCT was expressed from a bicistronic mRNA that 
includes an IRES and the selectable marker gene puromycine phosphotransferase to make sure 
that xCT is indeed expressed when the cells are under puromycine selection. This strategy of 
xCT expression has been used throughout the studies presented in this work. Overexpression of 
xCT in the BL cell line HH514 allowed us to address the question whether overexpression of 
the transporter is able to rescue BL cells from apoptosis under non-permissive growth 
conditions.  
The data presented provide evidence that overexpression of xCT light chain is sufficient 
to strongly increase the uptake capacity for L-cystine in HH514 cells. xCT-overexpressing 
cells had dramatically higher uptake capacity for L-cystine than control cells. Increased 
availability of L-cystine rendered BL cells more resistant to cell death induced either by 
seeding the cells at low cell density or by depleting glutathione by BSO. xCT-overexpressing 
cells were protected from cell death induced by seeding the cells at critical cell density. The 
xCT-overexpressing cells were able to survive and proliferate at low cell density that was non-
permissive for control cells. By xCT overexpression we achieved a similar “rescue” effect as 
described previously for supplementation of the medium with thiol compounds (45) and were 
able to protect BL cells from oxidative stress-induced cell death. These data provide conclusive 
evidence for the notion that availability of cystine and cysteine itself is the limiting factor for 
survival and proliferation of BL cells under our culture conditions in vitro.  
 
6.1.2 Overexpression of xCT renders cells resistant to induction of cell death by 
BSO 
 
The original hypothesis was that under nonpermissive growth conditions uptake of L-
cystine or L-cysteine becomes limiting for the survival and proliferation of HH514 cells by 
limiting the synthesis of glutathione. The question whether glutathione plays indeed such a 
decisive role in protection of cells from cell death was addressed by experiments in which the 
synthesis of glutathione was inhibited in xCT-overexpressing cells and control cells. The cells 
were treated with increasing concentrations of buthionine sulfoximine (BSO), an inhibitor of γ-
glutamyl-cysteinyl-synthetase (γ-GCS), the rate limiting enzyme in glutathione synthesis, to 
establish a putative correlation between cell survival/proliferation and intracellular GSH levels. 
These experiments provided compelling evidence that xCT-overexpressing cells can survive 
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and proliferate in the presence of 5 μM to 100 μM BSO, whereas control cells died at a 
concentration of 5 µM BSO in the first 48 hours of BSO treatment.  
 
6.2 Glutathione is not the key element of the antioxidant defense 
system that is activated by xCT overexpression in BL cells 
 
It was our first expectation that there is a threshold of glutathione in xCT-
overexpressing versus control cells that would discriminate between cell survival and death. If 
a threshold indeed exists, a prediction would be that xCT-overexpressing cells will have 
invariably higher glutathione levels than control cells. Determination of glutathione levels in 
BSO treated cells, however, clearly revealed that the glutathione levels were equally decreased 
in both, xCT-overexpressing and control cells. Most importantly, the glutathione level of 
control cells in the presence of 5 µM BSO (non-permissive for cell survival) was higher than 
that in xCT-overexpressing cells at higher BSO concentrations under which xCT-
overexpressing cells still could proliferate. These results rule out a putative threshold for the 
glutathione concentration that is compatible with cell survival and proliferation, and excludes a 
critical role for glutathione in the rescue from oxidative stress-induced cell death. Even though 
glutathione has been considered to be the most important redox and antioxidant defense 
system, recent data from several laboratories including our own strengthen the point that this 
long-standing paradigm has to be re-evaluated. Independent evidence that glutathione is indeed 
dispensable for cell proliferation has been provided by genetic means (127). Deletion of the 
gene for γ-glutamyl-cysteinyl-synthase (γ-GCS) in mice was found to be associated with early 
embryonic death around gestational day 8.5. Unexpectedly, the block of proliferation of γ-GCS 
deficient blastocyst-derived cell lines in culture could be overcome by N-acetylcysteine (NAC) 
even if glutathione was absent from the medium (122). These data clearly demonstrate that 
GSH itself is dispensable for proliferation when antioxidants are added to the growth medium. 
Apparently, beside glutathione several other redox couples participate in intracellular redox 
regulation. At least four related systems function in redox control: thioredoxine-1/thioredoxine 
reductase-1 (Trx1/TR1), thioredoxine-2/thioredoxine reductase-2 (Trx2/TR2), glutaredoxin-
1/GSH/glutathione reductase (Grx1/GSH/GR), and oxidase-linked protein disulfide isomerases 
(PDI) (79). In vitro experiments with CaCo2 cells have furthermore revealed that the 
extracellular redox potential defined by the ratio of extracellular cysteine to cystine is critical 
for cell proliferation independently from intracellular glutathione (77, 99).  
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6.3 Role of extracellular cysteine 
 
 Determination of the level of secreted mercaptans revealed a dramatic difference 
between xCT-overexpressing cells and control cells and clearly showed that proliferation of 
xCT-overexpressing cells under conditions, that are non-permissive for control cells, is 
associated with a dramatic increase in the level of extracellular small mercaptans. HPLC 
analysis revealed that the small mercaptan in the exracellular space is virtually exclusively 
cysteine. The difference in the extracellular cysteine level of xCT-overexpressing and vector-
transfected control cells became even more evident when cells were depleted of glutathione. 
Additionally, co-culture experiments revealed a feeder effect of xCT-overexpressing cells for 
vector-transfected control cells indicating that cysteine that is secreted by xCT-overexpressing 
cells is sufficient to maintain survival and proliferation of vector-transfected control cells. 
Thus, the question arises as to the protective mechanism of increased extracellular 
cysteine levels. Cysteine fulfills a wide range of different functions including disulfide 
formation, metal-binding, hydrolysis, electron donation and redox-catalysis (53). 
Thiol/disulfide reactions are in vivo substitution reactions with the protonated thiol group of 
cysteine acting as a nucleophile. Intracellularly, these reactions play a crucial role in the 
maintenance of the cellular redox balance in different redox couples such as GSSG/GSH, 
thioredoxin (Trx), protein disulfide isomerase (PDI) and glutaredoxin (Grx) (53). Given the 
pivotally important role of cysteine in redox active peptides and proteins, surprisingly little is 
known about the contribution of extracellular cysteine levels to the maintenance of the cellular 
redox balance. The low molecular weight thiol/disulfide pool consists predominantly of cystine 
and cysteine, and a generalized impact of the extracellular thiol/disulfide redox state on cell 
proliferation and/or apoptosis has been proposed. For instance, the redox state of the 
extracellular cysteine/cystine pool may affect cell proliferation by increasing the susceptibility 
of growth factor receptors to their ligands (77). 
Our data indicate the existence of an independent redox cycle, the cystine/cysteine 
cycle, that by itself protects the cells from cell death under conditions of GSH depletion. These 
findings support the notion that maintenance of the intra- and extracellular redox balance rather 
than the glutathione level itself is critical to protect HH514 cells from cell death.  
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6.4 The cystine/cysteine cycle 
 
The activity of xc- system contributes to driving the cystine/cysteine cycle and to 
maintaining the balance between cystine and cysteine in the cell culture medium. Cystine taken 
up by cells via xc- system, is reduced intracellulary to cysteine and part of cysteine is released 
back into the medium via the neutral amino acid transport system. Extracellular cysteine is 
rapidly oxidized to cystine by oxygen in the medium. Cystine uptake, reduction to cysteine, 
secretion of cysteine, and reoxidization to cystine thus constitute a redox cycle that is driven by 
the cystine glutamate exchange transporter (118, 152). The data presented provide compelling 
evidence that the cystine/cysteine cycle is able to protect cells from oxidative stress-induced 
cell death and to maintain survival and proliferation of xCT-overexpressing cells. The 
proposed model is presented in figure 35. 
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Figure 35. Schematic model for the cystine/cysteine cycle in the xCT-overexpressing HH514 cells. 
 
The question arises which molecules are providing the reducing equivalents for the 
reduction of cystine to cysteine inside the cells in untreated as compared to BSO-treated cells. 
In untreated cells, the glutathione system consisting of glutathione (GSH), glutaredoxin, 
glutathione reductase and NADPH, is the prime candidate. But what is reducing cysteine if 
glutathione synthesis is blocked by BSO? The cytosolic and mitochondrial thioredoxin-
thioredoxin reductase systems are the most likely candidates for taking over this function in 
BSO treated cells, either completely or in part. Our group has recently demonstrated that the 
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apoptosis-inducing function of BSO can be partly compensated by the thioredoxin system in 
fibroblasts derived from thioredoxin reductase 2 (Txnrd2) wild-type mice but not from Txnrd2 
knockout mice (32). But a role for glutathione can not be definitively ruled out. Since 
inhibition of glutathione synthesis by BSO is incomplete and only leads to reduced levels of 
cellular GSH of around 10-20% as compared to non-treated cells, the data from this work do 
not rule out the possibility that small amounts of residual glutathione found in BSO treated 
cells do play a role for the inititation or maintenance of the cystine/cysteine cycle. The fact that 
BSO interferes with proliferation in a dose-dependent manner might suggest that residual 
glutathione may indeed play a role in initiating and/or sustaining the cystine/cysteine cycle. 
Whether glutathione is completely dispensable for reduction of cystine can only be answered 
by genetic means. If so, cells deficient in γ-GCS that are overexpressing xCT should become 
independent of NAC. If they remain dependent on NAC, this would indicate that residual 
glutathione is indeed required to sustain the cystine/cysteine cycle.  
The cystine/cysteine cycle also seems to be important in maintaining the redox status in 
the nervous system and has also been proposed to play a role in the resistance of cancer cells to 
chemotherapy (118). In the brain, reactive oxygen species are produced at a higher rate because 
of the high consumption of oxygen, and ROS are involved in the pathogenesis of various 
neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral 
sclerosis (8). Sato and colleagues showed (118) that xc- system is expressed predominantly in 
regions facing the cerebrospinal fluid (CSF) and contributes to the clearance of cystine from 
CSF. Clearance of cystine via system xc- in the cells facing CSF and release of cysteine from 
the cells via neutral amino acid transporters may contribute to maintaining the reduced state in 
the CSF. The cysteine/cystine cycle could thus serve as a major redox buffer in the 
extracellular medium (118) thus playing an important role in the protection against oxidative 
stress. 
Elevated levels of extracellular glutamate can induce seizure and cause excitotoxic 
neuronal cell death. This is normaly prevented by astrocyte Na+-dependent glutamate uptake. 
However, human malignant glioma cells display strong Na+-independent cystine-glutamate 
exchange activity (152). In malignant glioma cells, unlimited activity of the cystine/cysteine 
cycle cycle may thus lead to release of glutamate at concentrations that can induce widespread 
neurotoxicity.  
The most difficult question that arises from this work addresses the mechanism how 
extracellular cysteine may protect cells from cell death. The cysteine/cystine redox couple 
participates in the redox balance and in the equilibrium with other redox pairs like GSSG/GSH, 
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thioredoxin (Trx), glutaredoxin (Grx) and protein thiols/protein disulfides through disulfide 
isomerase (PDI). Jones et al. have recently reported that the steady-state redox potential of the 
cysteine/cystine couple in cells is considerably more oxidized than that of GSH/GSSG and 
thioredoxin (79). The cystine/cysteine redox couple is thus regulated independently of 
GSH/GSSG and is sufficiently oxidized to contribute to redox signaling and redox control on 
its own (79). In vitro experiments with CaCo2 cells had furthermore revealed that the 
extracellular redox potential defined by the ratio of extracellular cysteine to cystine is critical 
for cell proliferation and is independent of glutathione (77, 99). Jonas et al. (77) suggested that 
the proliferative effect of extracellular cystine/cysteine on CaCo2 cells might be due to an 
interaction with growth factor signaling eventually occurring at the cell surface. There are also 
suggestions that nutrients like glutamine and keratinocyte growth factor stimulate cell 
proliferation of CaCo2 cells through modulation of the extracellular cysteine/cystine ratio 
without any effect on the intracellular GSH/GSSG ratio (76). 
Meanwhile it has become well accepted that intra- and extracellular redox changes have 
a strong impact on signaling pathways that regulate cell survival or cell death (1, 30, 77, 80, 
106, 120). Schafer and Buettner in 2001 (120) proposed a model where proliferation, 
differentiation, apoptosis and necrosis are coupled to a given redox status. According to this 
model, changes in the fate of a cell are associated with or are dependent on changes in the 
reduction potential of various redox couples.  
The ultimate challenge will be to define the molecules on the cell surface that are the 
targets of the cystine/cysteine cycle and have to be maintained in reduced form to allow cell 
survival and proliferation.  
 
6.5 The cystine/cysteine cycle protects cells from cell death initiated 
in mitochondria  
 
We finally attempted to clarify whether there is a crosstalk of the cystine/cysteine cycle 
to other pathways that regulate susceptibility versus resistance to apoptosis and to identify the 
relay stations linking the different pathways. To address this question we have studied in which 
subcellular compartment the cystine/cysteine cycle accomplishes its antiapoptotic action. 
Oxidative stress is a common element of apoptosis induced by various stimuli. We could show 
that in xCT-overexpressing cells the cystine/cysteine cycle suppresses the production of ROS 
under glutathione depletion, suggesting that control cells were dying of oxidative stress-
induced cell death. The cystine/cysteine cycle thus can rescue cells from cell death, either by 
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scavenging intracellular ROS itself or by inducing another intracellular 
antioxidant/antiapoptotic system. Since mitochondria harbour the respiratory chain and are the 
primary targets exposed to oxygen radicals as leakage products of incomplete oxygen 
reduction, we assumed that oxidative stress-induced cell death is initiated at the mitochondria. 
We have therefore studied the role of mitochondria in the induction of cell death by BSO. Our 
data show that BSO induces breakdown of the mitochondrial membrane potential, caspase 
activation and DNA fragmentation, confirming that the mitochondrial death pathway is in fact 
involved. The reduction of the mitochondrial membrane potential was inhibited in xCT-
overexpressing cells indicating that the cystine/cysteine cycle, presumably by secretion of 
cysteine, is able to counteract BSO-induced oxidative damage and to suppress dysfunction of 
mitochondria. Since alterations in mitochondrial function are critically involved in the 
induction of cell death, we wanted to determine whether caspases and if so, which type of 
caspases are activated during BSO-induced cell death. Using fluorogenic peptide substrates to 
measure caspase activity, caspases 2, 3, 8 and 9 were found to be activated after 48 hours of 
BSO treatment in the control cells. Activation of caspases was inhibited by xCT-
overexpression. Attempts to block BSO-induced cell death in vector-transfected cells by the 
caspase inhibitor zVAD-fmk failed (data not shown) suggesting that redundant pathways to kill 
the cells have been activated by BSO. To see whether cell death induced by BSO, as defined 
by PI-positivity of the cells, is preceded by the appearance of Annexin V-positive apoptotic 
cells, kinetic experiments with low BSO concentrations were performed.  These experiments 
revealed a substantial increase in PI-positive cells (necrosis-like cell death) without an 
intermediate concomitant increase in the number of Annexin V-positive apoptotic cells (data 
not shown). It has been proposed that apoptosis and necrosis might share common mediators 
such as Ca2+ and caspases (85) and that signaling of the Fas receptor initiates both, apoptotic 
and necrotic cell death (136). We conclude that in our experimental setting cell death advanced 
rapidly and did not allow to define an intermediate stage of Annexin-V-positive, PI-negative 
cells.  This is compatible with the model of Schafer and Buettner (120) who proposed that, by 
decreasing the reducing potential of redox couples, a series of switches may be activated that 
drive the cells from proliferation through various stages of differentiation. When the redox 
environment cannot be maintained, apoptosis and finally, when the redox potential is 
completely breaking down, necrosis ensue. It was proposed that glutathione would control the 
protein thiol/disulfide equilibrium and thereby drive the cellular switches. Our data imply that 
under conditions of glutathion depletion the cysteine/cystine redox couple takes over the role 
hitherto assigned to glutathione. 
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Overexpression of xCT does not appear to have an impact on the expression of  genes 
that are known to regulate apoptosis in mitochondria such as the antiapoptotic proteins Bcl-2, 
Bcl-xL, and Bcl-w as well as the proapoptotic members of the Bcl-2 family, namely Bax, Bak, 
Bad, Bid, Bik and Bim. We cannot exclude an effect of the cystine/cysteine cycle on a gene or 
gene products that has not been studied. The data, however, strongly suggest that the 
cystine/cysteine cycle has its own impact on regulation of apoptosis by maintaining the extra- 
and intracellular redox balance including the intramitochondrial membrane potential rather 
than modulating the expression of pro- and /or antiapoptotic genes.  
 
6.6 OUTLOOK 
 
Several important questions have arisen from this work, but still had to remain open. 
Firstly, what are the target molecules (the molecular switches) that are under redox regulation 
by the cystine/cysteine cycle in our cellular system and that are essential for the decision 
whether a cell will survive or die? Secondly, what is providing the reducing equivalent under 
conditions of glutathione depletion inside the cells? These questions might be addressed by 
using toxic chemicals that selectively react with –SH groups and mark the proteins or by 
knocking out particular molecules (such as thioredoxin mutants) in xCT-overexpressing cells.  
As the maintenance of a reducing extracellular environment is so critical for cell 
survival, it appears likely that molecular processes taking place at the cell surface or in the cell 
membrane play a decisive role. Extracellular cysteine levels may thus regulate cell survival e.g. 
through activation of cell surface receptors. It may also regulate certain intracellular pathways 
such as production and secretion of growth factors and cytokines, signal transduction 
mechanisms and the activity of transcription factors. Many extracellular receptors are tyrosine 
kinases or regulated by tyrosine kinases and phosphatases and the activity of tyrosine 
phosphatases is known to be inhibited by oxygen radicals. Many tyrosine kinase receptors are 
activating the serine-threonine kinase Akt/protein kinase B (PKB), a kinase playing a pivotal 
role in the regulation of cell survival and cell death thus coupling growth factor receptor 
signaling to the regulation of cell survival. Another serine-threonine kinase playing an 
important role in stress-induced signaling is apoptosis signal-regulating kinase (ASK) that is 
known to be regulated by thioredoxin.  
Another question is whether the cystine/cysteine cycle requires basal amounts of 
glutathione in cells below the threshold detected in our experiments. The work presented here 
could not rule out the possibility that minor levels of glutathione which remain in the cell after 
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BSO treatment may play a role in initiating reduction of cystine into cysteine. This question 
can only be answered by genetic means when xCT is overexpressed in cells that are deficient in 
glutathione synthesis due to a defect of γ-glutamyl-cysteine-snythetase (γ-GCS) and 
concomitant pharmacological inhibition of γ-glutamyl-transpeptidase which may generate γ-
glutamyl-cysteine from glutamine and provide a salvation pathway for the synthesis of small 
amounts of glutathione.  
It has already been shown that during antigen exposure proliferation and activation of T 
helper cells is dependent on cysteine secreted from antigen-presenting cells (123). A similar 
cooperation has been observed in the nervous system, where neuronal cells receive cysteine 
through the secretion from the glia cells (109). Therefore, the cystine/cysteine cycle most likely 
plays an important role in maintaining the redox status in the nervous system (118). The 
analysis of the phenotype of xCT knock-out mice might open the possibility to study the role 
of the cystine/cysteine cycle in physiological and pathophysiological conditions such as under 
ischemic stress and infection. It is another important question to understand under which 
conditions the activity of the cystine/cysteine cycle may have adverse effects to the organism. 
As proposed by Ye et al., 1999 (151, 152), unlimited activity of the cystine/cystine cycle due to 
xCT overexpression in malignant glioma cells might lead to a dramatic increase in the 
secretion of glutamate associated with increased glutamate toxicity and neuronal death. In the 
hematopoetic system, the particular sensitivity of the cells to irradiation may be related to the 
limited uptake capacity for cystine. Limited activity of the cystine/cysteine cycle may also be 
necessary for an orchestrated regulation of apoptosis in the immune system. Low activity of the 
xc- system in B and T cells may be prerequisite to render the immune system highly dynamic. 
Generation of transgenic “gain-of-function” mice will enable us to address this question. 
Drug resistance is one of the most serious problems in cancer chemotherapy. For a long 
time it has been known that irradiation leads to a decrease in cellular thiols and that thiols 
protect cells against the effects of irradiation. Drugs which are commonly used as 
antineoplastic drugs in the treatment of malignancies reduce glutathione levels in various cell 
types (83). It has been shown that the activity of system xc- can determine resistance to 
cisplatin in a human ovarian cancer cell line (102). It will be important to examine in a more 
systematic fashion the possible role of the cystine/cysteine cycle in drug resistance in cancer 
cells. 
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The high susceptibility of Burkitt lymphoma (BL) cells to apoptosis at low cell density 
or in the absence of feeder cells is due to their low uptake capacity for cystine. The cells have 
an efficient uptake system for cysteine but not cystine. Availability of cystine or cysteine is the 
rate limiting step in the synthesis of glutathione, the major cellular antioxidant. Irradiated 
fibroblast feeder cells support the growth of Burkitt´s lymphoma cells because they can 
efficiently take up cystine and secrete it to cocultured BL cells as cysteine. Cystine, the 
predominant form in plasma, extracellular body fluids and in cell culture medium, is imported 
into the cells by the cystine-glutamate exchange transporter (xc- system), a heterodimeric amino 
acid transporter consisting of two subunits, xCT light chain and 4F2 heavy chain, that imports 
cystine and exports glutamate. In the absence of feeder cells and at low cell density, survival 
and proliferation of BL cells is dependent on thiol compounds, such as α-thioglycerol or β-
mercaptoethanol, added to the medium together with scavengers of oxygen radicals, that 
generate mixed disufides and thus promote the uptake of cysteine and the synthesis of 
glutathione. To investigate the impact of system xc- on cell proliferation and apoptosis we 
transfected the BL cell line HH514 with the gene for xCT, the substrate specific subunit of 
system xc-. 
In this work, for the first time a stable overexpression system for Burkitt´s lymphoma 
cells has been developed for xCT light chain, the subunit of system xc- conferring substrate 
specificity. The data show that overexpression of xCT is sufficient to promote cystine uptake 
and to rescue BL cells from oxidative –stress-induced cell death mediated by seeding the cells 
at low cell density. Most importantly, xCT-overexpressing cells were able to maintain cell 
survival and proliferation also under conditions of inhibiting glutathione synthesis by 
buthionine sulfoximine (BSO) ruling out glutathione as the critical determinant in the decision 
between cell survival and cell death.  In the supernatant of xCT-overexpressing cells, 
extracellular cysteine levels were highly elevated as compared to vector-transfected control 
cells. The data support the model that the activity of system xc- supports cell survival and 
proliferation by driving an independent redox cycle, the cystine/cysteine cycle that consists of 
cystine uptake, intracellular reduction to cysteine, secretion of cysteine into the medium and 
reoxidization of cysteine to cystine by air oxygen and is able to generate the cell´s own 
reducing environment. xCT overexpression as well as supply of the cells with cysteine by 
treatment with α-thioglycerol protected HH514 cells efficiently from BSO-induced breakdown 
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of the mitochondrial membrane potential and the execution phase of cell death mediated by 
capsase activation and DNA fragmentation. The data suggest that BSO-induced cell death is 
initiated at the mitochondria. No difference in the expression of p53 and pro- and antiapoptotic 
members of the Bcl-2 family were observed when xCT-overexpressing cells and vector-
transfected control cells were compared suggesting that the crucial function of the 
cystine/cysteine cycle is to maintain the extracellular, intracellular and intramitochondrial 
redox balance rather than to modulate the expression of genes that regulate susceptibility 
versus resistance to cell death.  
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